<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        7-663-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        HALAVEN
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ERIBULIN MESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.44
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1475.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BSP PHARMACEUTICALS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BSP PHARMACEUTICALS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            EISAI EUROPE LIMITED
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XX41
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>HALAVEN contains the active substance eribulin and is an anti-cancer medicine which works by stopping the growth and spread of cancer cells.</p><p>&nbsp;</p><p>It is used in adults for locally advanced or metastatic breast cancer (breast cancer that has spread beyond the original tumour) when at least one other therapy has been tried but has lost its effect.</p><p>&nbsp;</p><p>It is also used in adults for advanced or metastatic liposarcoma (a type of cancer that arises from fat tissue) when previous therapy has been tried but has lost its effect.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use HALAVEN:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to eribulin mesilate or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are breast-feeding</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or nurse before using HALAVEN:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a fever or an infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience numbness, tingling, prickling sensations, sensitivity to touch or muscle weakness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have heart problems</p><p>&nbsp;</p><p>If any of these affects you, tell your doctor who may wish to stop treatment or reduce the dose.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>&nbsp;</p><p>Halaven is not recommended for children aged under 18 with paediatric sarcomas as it is not yet known how well it works in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and HALAVEN</strong></p><p>Tell your doctor if you are using, have recently used or might use any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>HALAVEN may cause serious birth defects and should not be used if you are pregnant unless it is thought clearly necessary after carefully considering all the risk to you and the baby. It may also cause future permanent fertility problems in men if they take it and they should discuss this with their doctor before starting treatment. Women of childbearing age should use effective contraception during and up to 3 months after treatment with HALAVEN.</p><p>&nbsp;</p><p>HALAVEN must not be used during breast-feeding because of the possibility of risk to the child.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>HALAVEN may cause side effects such as tiredness (very common) and dizziness (common). Do not drive or use machines if you feel tired or dizzy.</p><p>&nbsp;</p><p><strong>HALAVEN contains ethanol (alcohol)</strong></p><p>This medicine contains small amounts of ethanol (alcohol), less than 100&nbsp;mg in a vial.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>HALAVEN will be given to you by a doctor or nurse as an injection into a vein, over a period of 2 to 5 minutes. The dose you will receive is based on your body surface area (expressed in squared metres, or m<sup>2</sup>) which is calculated from your weight and height. The usual dose of HALAVEN is 1.23&nbsp;mg/m<sup>2</sup>, but this may be adjusted by your doctor based on your blood test results or other factors. To ensure that the whole dose of HALAVEN is given it is recommended that a saline solution is flushed into the vein after HALAVEN is given.</p><p>&nbsp;</p><p><strong>How often will you be given HALAVEN?</strong></p><p>HALAVEN is usually given on Days 1 and 8 of every 21-day cycle. Your doctor will determine how many cycles of treatment you should receive. Depending on the results of your blood tests, the doctor may need to delay administration of the medicine until the blood tests return to normal. The doctor may also then decide to reduce the dose you are given.</p><p>&nbsp;</p><p>If you have any further questions about the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If you experience any of the following serious symptoms, stop taking HALAVEN and seek medical attention straightaway:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, with a racing heart beat, rapid shallow breathing, cold, pale, clammy or mottled skin and/or confusion. These may be signs of a condition called sepsis &ndash; a severe and serious reaction to an infection. Sepsis is uncommon (may affect up to 1 in 100 people) and can be life-threatening and may result in death.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any difficulty breathing, or swelling of your face, mouth, tongue or throat. These could be signs of an uncommon allergic reaction (may affect up to 1 in 100 people).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious skin rashes with blistering of the skin, mouth, eyes and genitals. These may be signs of a condition called Stevens Johnson syndrome/toxic epidermal necrolysis. The frequency of this condition is not known but it can be life-threatening.</p><p>&nbsp;</p><p>Other side effects:</p><p>&nbsp;</p><p>Very common side effects (may affect more than 1 in 10 people) are:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in the number of white blood cells or red blood cells</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness or weakness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, vomiting, constipation, diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness, tingling or prickling sensations</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite, weight loss</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty breathing, cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in the joints, muscles and back</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss</p><p>&nbsp;</p><p>Common side effects (may affect up to 1 in 10 people) are:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in the number of platelets (which may result in bruising or taking longer to stop bleeding)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection with fever, pneumonia, chills</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast heart rate, flushing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vertigo, dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased production of tears, conjunctivitis (redness and soreness of the surface of the eye), nosebleed</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dehydration, dry mouth, cold sores, oral thrush, indigestion, heartburn, abdominal pain or swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of soft tissues, pains (in particular chest, back and bone pain), muscle spasm or weakness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mouth, respiratory and urinary tract infections, painful urination</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore throat, sore or runny nose, flu-like symptoms, throat pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver function test abnormalities, altered level of sugar, bilirubin, phosphates, potassium, magnesium or calcium in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inability to sleep, depression, changed sense of taste</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, itching, nail problems, dry or red skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive sweating (including night sweats)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ringing in the ears</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clots in the lungs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shingles</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the skin and numbness of the hands and feet</p><p>&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people) are:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clots</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal liver function tests (hepatoxicity)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney failure, blood or protein in the urine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Widespread inflammation of the lungs which may lead to scarring</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mouth ulcers</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension</p><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1000 people) are:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A serious disorder of blood clotting resulting in the widespread formation of blood clots and internal bleeding.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not store above 25&deg;C, do not freeze.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is eribulin. Each 2&nbsp;ml vial contains eribulin mesilate equivalent to 0.88&nbsp;mg eribulin.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are ethanol and water for injections, with hydrochloric acid and sodium hydroxide possibly present in very small amounts.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                HALAVEN is a clear, colourless aqueous solution for injection provided in glass vials containing 2 ml. Each carton contains 1 vial.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Eisai Europe Limited</p><p>European Knowledge Centre</p><p>Mosquito Way</p><p>Hatfield</p><p>Hertfordshire</p><p>AL10 9SN</p><p>United Kingdom</p><p>&nbsp;</p><p><strong>Bulk </strong><strong>Manufacturer</strong><strong>:</strong></p><p>BSP Pharmaceuticals S.p.A.</p><p>Via Appia km 65,561 (loc. Latina Scalo)</p><p>04013 Latina (LT)</p><p>Italy</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Batch Releaser:</strong></p><p>Eisai Manufacturing Limited,</p><p>European Knowledge Centre,</p><p>Mosquito Way,</p><p>Hatfield,</p><p>Hertfordshire,</p><p>AL10 9SN,</p><p>United Kingdom</p><p>For any information about this product, please contact the local representative of the Marketing Authorisation Holder:</p><p>ABDULRAHMAN ALGOSAIBI GTC</p><p>P.O. Box 215 - Riyadh 11411</p><p>Tel. 011 4793000</p><p>Fax. 011 4771374</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 01/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي دواء هالافين &nbsp;على المادة الفعَّالة إريبولين وهو دواء مُضاد للسرطان يعمل عن طريق إيقاف نمو وانتشار خلايا السرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وهو يُستَخدَم في البالغين لعلاج سرطان الثدي المتقدم موضعيًّا أو النقيلي (سرطان الثدي الذي قد انتشر أبعد من الورم الأصلي) عند محاولة العلاج بعلاج آخر واحد على الأقل وفقدانه لفعَّاليته.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستَخدَم الدواء أيضًا في البالغين لعلاج الساركوما الشحمية المتقدمة أو النقيلية (نوع من أنواع السرطان الذي ينشأ من النسيج الدهني) في حال تم تجربة علاج سابق ولكنه فقد فعَّاليته.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يحذر استخدام دواء هالافين &nbsp;في الحالات الآتية</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه إريبولين مسيلات أو أي من المكونات الأخرى بهذا الدَّواء (المدرجة بالقسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مرضعًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الممرض(ة) قبل استخدام دواء هالافين &nbsp;في الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا بحُمى أو عدوى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرَّضت لشعور بالتنميل أو الوخز أو الثقب، أو حساسية عند لمس الأشياء أو ضعف العضلات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل بالقلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصابك أي مما سبق، فأخبر طبيبك وهو بدوره قد يرغب في إيقاف العلاج أو خفض الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينصح باستخدام بدواء هالافين في الأطفال تحت سن 18 عامًا المُصابين بالساركومات التي تُصيب الأطفال فمدى كفاءة فعاليته في هذه الفئة العمرية غير معروف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام دواء هالافين &nbsp;مع أدوية أخرى</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تكون تستخدم أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">قد يُسبب دواء هالافين &nbsp;عيوبًا خلقية خطيرة ويجب عليكِ عدم استخدامه إذا كنتِ حاملًا إذا لم يُعتَقَد أنه ضروري بشكل واضح بعد الوضع في الاعتبار بعناية جميع المُخاطر التي ستتعرَّضين لها وسيتعرَّض لها الطفل. قد يُسبب أيضًا في المستقبل مشاكل دائمة في الخصوبة لدى الرجال إذا تناولوه ويجب عليهم مناقشة ذلك مع أطبائهم قبل بدء العلاج. يجب على السيدات اللاتي لديهن القدرة على الحمل استخدام وسيلة فعَّالة لمنع الحَمْل أثناء العلاج بدواء هالافين &nbsp;وحتى 3 أشهر بعده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم استخدام دواء هالافين &nbsp;أثناء الرضاعة الطبيعيَّة بسبب إمكانية وجود خطورة على الطفل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يُسبب دواء هالافين &nbsp;آثارًا جانبيةً مثل التَّعب (شائع جدًّا) والدوخة (شائع). لا تمارس القيادة أو تستخدم الآلات إذا شعرت بالتَّعب أو الدوخة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي دواء هالافين &nbsp;على الإيثانول </strong><strong>(</strong><strong>الكحول</strong><strong>)</strong></p><p dir="RTL">يحتوي هذا الدَّواء على كميات قليلة من الإيثانول (الكحول)، أقل من 100 ملغ في الزجاجة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيُعطى لك دواء هالافين &nbsp;من قِبَل الطبيب أو الممرض(ة) في هيئة حَقْن في الوريد، على مدار فترة قدرها 2 إلى 5 دقائق. تستند الجرعة التي ستتلقاها على مساحة سطح جسمك (يتم التَّعبير عنها بالمتر المربع أو م<sup>2</sup>) والتي سيتم حسابها من خلال وزنك وطولك. الجرعة المُعتادة من دواء هالافين &nbsp;هي1,23 &nbsp;&nbsp;ملغ/ متر مربع، ولكن قد يُعدِّلها طبيبك استنادًا إلى نتائج اختبارات الدَّم لديك أو عوامل أخرى. لضمان إعطاء جرعة دواء هالافين &nbsp;بالكامل، يُوصى بإعطاء محلول ملحي في الوريد بعد إعطاء دواء هالافين .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كم عدد المرات التي سيُعطى لك فيها دواء هالافين ؟</strong></p><p dir="RTL">يُعطى دواء هالافين &nbsp;عادةً في الأيام 1 و8 كل دورة مدتها 21 يومًا. قد يُحَدد طبيبك عدد الدورات من العلاج التي عليك تلقيها. وفقًا لنتائج اختبارات الدَّم الخاصة بك، قد يحتاج الطبيب إلى تأخير إعطاء الدَّواء حتى تعود نتائج اختبارات الدَّم إلى الوضع الطبيعي. قد يُقرر أيضًا الطبيب خفض الجرعة التي يتم إعطاؤها لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اسأل طبيبك في حالة وجود أية أسئلة إضافية متعلقة باستخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تعرَّضت لأي من الأعراض الخطيرة التَّالية، فتوقف عن تناوُل دواء هالافين &nbsp;واطلب العناية الطبية فورًا:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمى، مصحوبة بتسارع في نبضات القلب، تَنَفُّس ضَحْل سريع، برودة الجلد، وشحوبه، وتنديه بالعرق أو تبقعه و/أو ارتباك. قد تكون هذه علامات لحالة تُسمى تعفُّن الدَّم &ndash; أحد التفاعلات الشديدة والخطيرة لعدوى ما. تُعد حالة تعفن الدَّم غير شائعة (قد تصيب ما يصل إلى شخص واحد من بين كل 100 شخص) وقد تكون مهددة للحياة وربما تؤدي إلى الوفاة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -أي صعوبة في التَّنفس، أو تورُّم بالوجه أو الفم أو اللسان أو الحَلْق. قد تكون هذه علامات للإصابة بتفاعلات حساسية غير شائعة (قد تصيب ما يصل إلى شخص واحد من بين كل 100&nbsp;شخص).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي خطير مصحوب بظهور بثور بالجلد والفم والعينين والأعضاء التناسلية. قد تكون هذه علامات للإصابة بحالة تُسمى متلازمة ستيفنز جونسون/ انحلال البشرة النخري التَّسَمُّمِي. معدل تكرار حدوث هذه الحالة غير معروف لكنها قد تكون مُهددة للحياة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الأخرى:</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الشائعة جدًّا (قد تصيب أكثر من شخص &nbsp;من بين كل 10&nbsp;أشخاص) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدَّم البيضاء أو عدد خلايا الدَّم الحمراء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب وضعف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان، قيء، إمساك، إسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتنميل أو الوخز أو الثقب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمّى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية، فقدان الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التَّنفس، سُعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل والعضلات والظهر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الشائعة (قد تصيب ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الصفائح الدَّموية (الأمر الذي قد يُؤدي إلى كدمات أو استغراق وقت أطول لإيقاف النزيف)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى مصحوبة بحُمى، التهاب رئوي، قشعريرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع ضربات القلب، احمرار الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار، دوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الإدماع، التهاب المُلْتَحِمَة (احمرار وتقرُّح سطح العين)، نزيف الأنف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف، جفاف الفم، قُرَح البرد، سُلَاق فموي، عُسْر الهضم، حموضة (حُرْقَةُ الفُؤاد)، ألم بالبطن أو تورُّم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم الأنسجة الرَّخوة، آلام (خاصةً ألم في الصدر والظهر والعظام)، تقلصات عضلية أو ضعف عضلي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بالفم والجهاز التَّنفسي والمسالك البولية، ألم عند التبوُّل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحَلْق، التهاب أو سيلان الأنف، أعراض شبيهة بأعراض الأنفلونزا، ألم بالحَلْق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية في اختبار وظائف الكبد، تغيُّر مستوى السُّكَّر أو البيليروبين أو الفوسفات أو البوتاسيوم أو الماغنسيوم أو الكالسيوم في الدَّم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على النوم، الاكتئاب، تغيُّر حاسة التذوُّق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، حكة، مشاكل بالأظافر، جفاف الجلد أو احمراره</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرق مفرط (بما في ذلك التَّعرق الليلي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طنين بالأذن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات دموية بالرئتين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القوباء المنطقية (هِرْبِس نُطاقِيّ)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم الجلد وتنميل باليدين والقدمين</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية غير الشائعة (قد تصيب ما يصل إلى شخص واحد منبين كل 100 شخص) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات الدَّم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية باختبارات وظائف الكبد (تَسَمُّمُ الكَبِد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل كلوي، وجود دم أو بروتينات بالبول</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئتين واسع الانتشار الذي قد يُؤدي إلى التندُّب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قُرح بالفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية النَّادرة (قد تصيب ما يصل إلى شخص واحد من بينكل 1000&nbsp;شخص) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب حاد في تخثر الدَّم مما قد يُؤدي إلى تكوين وانتشار الجلطات الدموية وحدوث نزيف داخلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى طبيبك أو الممرض(ة).ويشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة.من خلال إبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ في درجة حرارة لا تزيد عن&nbsp; 25 درجة مئوية، لا يُجمد.&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية والزجاجة بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما الذي يحتوي عليه دواء هالافين &nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي إريبولين. تحتوي كل زجاجة بحجم 2 مللي لتر على إريبولين مسيلات بما يُعادِل 0,88 ملغ إريبولين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المُكوِّنات الأخرى هي إيثانول وماء للحَقْن، مع حمض الهيدروكلوريك وهيدروكسيد الصوديوم، قد يتواجدون بكميات صغيرة للغاية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دواء هالافين &nbsp;هو محلول مائي للحَقْن صافٍ وعديم اللون، يتم توفيره في زجاجات زجاجية تحتوي على 2 مللي لتر.&nbsp; تحتوي كل عبوة كرتونية على زجاجة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التَّسويق</strong></p><p>Eisai Europe Limited</p><p>European Knowledge Centre</p><p>Mosquito Way</p><p>Hatfield</p><p>Hertfordshire</p><p>AL10 9SN</p><p>United Kingdom</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة التَّصنيع</strong><strong>:</strong></p><p>BSP Pharmaceuticals S.p.A.</p><p>Via Appia km 65,561 (loc. Latina Scalo)</p><p>04013 Latina (LT)</p><p>Italy</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة إصدار التَّشغيلة</strong><strong>:</strong></p><p dir="RTL">Eisai Manufacturing Limited,</p><p dir="RTL">European Knowledge Centre,</p><p dir="RTL">Mosquito Way,</p><p dir="RTL">Hatfield,</p><p dir="RTL">Hertfordshire,</p><p dir="RTL">AL10 9SN,</p><p dir="RTL">United Kingdom</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لمزيد من المعلومات حول هذا الدواء، الرجاء الاتصال بالممثل المحلى لمالك حق التسويق</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ABDULRAHMAN ALGOSAIBI GTC</p><p dir="RTL">P.O. Box 215 - Riyadh 11411</p><p dir="RTL">Tel: 011 4793000</p><p>Fax: 011 4771374</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النَّشرة في 01/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                HALAVEN 0.44 mg/ml solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ml contains eribulin mesilate equivalent to 0.44 mg eribulin. 
Each 2 ml vial contains eribulin mesilate equivalent to 0.88 mg eribulin.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).

Clear, colourless aqueous solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HALAVEN is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease (see section&nbsp;5.1). Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.</p><p>&nbsp;</p><p>HALAVEN is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HALAVEN should only be administered under the supervision of a qualified physician experienced in the appropriate use of cytotoxic medicinal products.</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dose of eribulin as the ready to use solution is 1.23&nbsp;mg/m<sup>2</sup> which should be administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21‑day cycle.</p><p>&nbsp;</p><p><strong>Please note:</strong></p><p>In the EU the recommended dose refers to the base of the active substance (eribulin). Calculation of the individual dose to be administered to a patient must be based on the strength of the ready to use solution that contains 0.44&nbsp;mg/ml eribulin and the dose recommendation of 1.23&nbsp;mg/m<sup>2</sup>. The dose reduction recommendations shown below are also shown as the dose of eribulin to be administered based on the strength of the ready to use solution.</p><p>&nbsp;</p><p>In the pivotal trials, the corresponding publications and in some other regions e.g. the United States and Switzerland, the recommended dose is based on the salt form (eribulin mesilate).</p><p>&nbsp;</p><p>Patients may experience nausea or vomiting. Antiemetic prophylaxis including corticosteroids should be considered.</p><p>&nbsp;</p><p><em><u>Dose delays during therapy</u></em></p><p>&nbsp;</p><p>The administration of HALAVEN should be delayed on Day 1 or Day 8 for any of the following:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Absolute neutrophil count (ANC) &lt;&nbsp;1&nbsp;x&nbsp;10<sup>9</sup>/l</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Platelets &lt;&nbsp;75&nbsp;x&nbsp;10<sup>9</sup>/l</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 3 or 4 non-hematological toxicities.</p><p>&nbsp;</p><p><em><u>Dose reduction during therapy</u></em></p><p>&nbsp;</p><p>Dose reduction recommendations for retreatment are shown in the following table.</p><p><strong>Dose reduction recommendations </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:564px"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse reaction after previous HALAVEN administration</strong></p></td><td style="vertical-align:top"><p><strong>Recommended dose of eribulin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Haematological:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ANC &lt; 0.5 x 10<sup>9</sup>/l lasting more than 7 days</p></td><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>0.97&nbsp;mg/m<sup>2</sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ANC &lt; 1 x 10<sup>9</sup>/l neutropenia complicated by fever or infection</p></td></tr><tr><td style="vertical-align:top"><p>Platelets &lt; 25 x 10<sup>9</sup>/l thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Platelets &lt; 50 x 10<sup>9</sup>/l thrombocytopenia complicated by haemorrhage or requiring blood or platelet transfusion</p></td></tr><tr><td style="vertical-align:top"><p><strong>Non-haematological:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Any Grade 3 or 4 in the previous cycle</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reoccurrence of any haematological or non-haematological adverse reactions as specified above</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Despite reduction to 0.97&nbsp;mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>0.62&nbsp;mg/m<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Despite reduction to 0.62&nbsp;mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>Consider discontinuation</p></td></tr></tbody></table><p>&nbsp;</p><p>The dose of eribulin should not be re-escalated after it has been reduced.</p><p>&nbsp;</p><p><em><u>Patients with hepatic impairment</u></em></p><p><strong><em><u>&nbsp;</u></em></strong></p><p><em>Impaired liver function due to metastases</em></p><p>The recommended dose of eribulin in patients with mild hepatic impairment (Child-Pugh A) is 0.97&nbsp;mg/m<sup>2</sup> administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21‑day cycle. The recommended dose of eribulin in patients with moderate hepatic impairment (Child-Pugh B) is 0.62&nbsp;mg/m<sup>2</sup> administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21‑day cycle.</p><p>Severe hepatic impairment (Child-Pugh C) has not been studied but it is expected that a more marked dose reduction is needed if eribulin is used in these patients.</p><p>&nbsp;</p><p><em>Impaired liver function due to cirrhosis</em></p><p>This patient group has not been studied. The doses above may be used in mild and moderate impairment but close monitoring is advised as the doses may need readjustment.</p><p>&nbsp;</p><p><em><u>Patients with renal impairment</u></em></p><p>&nbsp;</p><p>Some patients with moderately or severely impaired renal function (creatinine clearance &lt;50&nbsp;ml/min) may have increased eribulin exposure and may need a reduction of the dose. For all patients with renal impairment, caution and close safety monitoring is advised. (See section 5.2)</p><p>&nbsp;</p><p><em><u>Elderly patients</u></em></p><p>&nbsp;</p><p>No specific dose adjustments are recommended based on the age of the patient (see section 4.8).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>&nbsp;</p><p>There is no relevant use of HALAVEN in children and adolescents for the indication of breast cancer.</p><p>&nbsp;</p><p>The safety and efficacy of HALAVEN in children from birth to 18 years of age have not yet been established in soft tissue sarcoma. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>HALAVEN is for intravenous use. The dose may be diluted in up to 100&nbsp;ml of sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection. It should not be diluted in glucose 5% infusion solution. For instructions on the dilution of the medicinal product before administration, see section 6.6. Good peripheral venous access, or a patent central line, should be ensured prior to administration. There is no evidence that eribulin mesilate is a vesicant or an irritant. In the event of extravasation, treatment should be symptomatic. For information relevant to the handling of cytotoxic medicinal products see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
-	Breast-feeding

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Haematology</u></p><p>&nbsp;</p><p>Myelosuppression is dose dependent and primarily manifested as neutropenia (section 4.8). Monitoring of complete blood counts should be performed on all patients prior to each dose of eribulin. Treatment with eribulin should only be initiated in patients with ANC values &ge;&nbsp;1.5&nbsp;x&nbsp;10<sup>9</sup>/l and platelets &gt;&nbsp;100&nbsp;x&nbsp;10<sup>9</sup>/l.</p><p>&nbsp;</p><p>Febrile neutropenia occurred in &lt;&nbsp;5% of patients treated with eribulin. Patients experiencing febrile neutropenia, severe neutropenia or thrombocytopenia, should be treated according to the recommendations in section 4.2.</p><p>&nbsp;</p><p>Patients with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;3&nbsp;x&nbsp;upper limit of normal (ULN) experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia. Although data are limited, patients with bilirubin &gt;1.5&nbsp;x&nbsp;ULN also have a higher incidence of Grade 4 neutropenia and febrile neutropenia.</p><p>&nbsp;</p><p>Fatal cases of febrile neutropenia, neutropenic sepsis, sepsis and septic shock have been reported.</p><p>&nbsp;</p><p>Severe neutropenia may be managed by the use of granulocyte colony-stimulating factor (G-CSF) or equivalent at the physician&rsquo;s discretion in accordance with relevant guidelines (see section 5.1).</p><p>&nbsp;</p><p><u>Peripheral neuropathy</u></p><p>&nbsp;</p><p>Patients should be closely monitored for signs of peripheral motor and sensory neuropathy. The development of severe peripheral neurotoxicity requires a delay or reduction of dose (see section 4.2)</p><p>&nbsp;</p><p>In clinical trials, patients with pre-existing neuropathy greater than Grade 2 were excluded. However, patients with pre-existing neuropathy Grade 1 or 2 were no more likely to develop new or worsening symptoms than those who entered the study without the condition.</p><p>&nbsp;</p><p><u>QT prolongation</u></p><p><u>&nbsp;</u></p><p>In an uncontrolled open-label ECG study in 26&nbsp;patients, QT prolongation was observed on Day&nbsp;8, independent of eribulin concentration, with no QT prolongation observed on Day&nbsp;1. ECG monitoring is recommended if therapy is initiated in patients with congestive heart failure, bradyarrhythmias or concomittant treatment with medicinal products known to prolong the QT interval, including Class Ia and III antiarrhythmics, and electrolyte abnormalities. Hypokalaemia, hypocalcaemia or hypomagnesaemia should be corrected prior to initiating HALAVEN and these electrolytes should be monitored periodically during therapy. Eribulin should be avoided in patients with congenital long QT syndrome.</p><p>&nbsp;</p><p><u>Excipients</u></p><p><u>&nbsp;</u></p><p>This medicinal product contains small amounts of ethanol (alcohol), less than 100&nbsp;mg per dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Eribulin is mainly (up to 70%) eliminated through biliary excretion. The transport protein involved in this process is unknown. Eribulin is not a substrate of breast cancer resistance protein (BCRP), organic anion (OAT1, OAT3, OATP1B1, OATP1B3), multi-drug resistance-associated protein (MRP2, MRP4) and bile salt export pump (BSEP) transporters.</p><p><strong><em>&nbsp;</em></strong></p><p>No drug-drug interactions are expected with CYP3A4 inhibitors and inducers. Eribulin exposure (AUC and C<sub>max</sub>) was unaffected by ketoconazole, a CYP3A4 and P glycoprotein (Pgp) inhibitor, and rifampicin, a CYP3A4 inducer.</p><p>&nbsp;</p><p><u>Effects of eribulin on the pharmacokinetics of other medicines</u></p><p>&nbsp;</p><p><em>In vitro</em> data indicate that eribulin is a mild inhibitor of the important drug metabolising enzyme CYP3A4. No <em>in vivo</em> data are available. Caution and monitoring for adverse events is recommended with concomitant use of substances that have a narrow therapeutic window and that are eliminated mainly via CYP3A4-mediated metabolism (eg alfentanil, cyclosporine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus).</p><p><s>&nbsp;</s></p><p>Eribulin does not inhibit the CYP enzymes CYP1A2, 2B6, 2C8<em>,</em> 2C9, 2C19<em>,</em> 2D6 or 2E1 at relevant clinical concentrations.</p><p>&nbsp;</p><p>At relevant clinical concentrations, eribulin did not inhibit BCRP, OCT1, OCT2,<strong> </strong>OAT1, OAT3, OATP1B1 and OATP1B3 transporter-mediated activity.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>There are no data from the use of eribulin in pregnant women. Eribulin is embryotoxic, foetotoxic, and teratogenic in rats. HALAVEN should not be used during pregnancy unless clearly necessary and after a careful consideration of the needs of the mother and the risk to the foetus.</p><p>&nbsp;</p><p>Women of childbearing potential must be advised to avoid becoming pregnant whilst they or their male partner are receiving HALAVEN and have to use effective contraception during and up to 3 months after treatment.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p>It is unknown whether eribulin/metabolites are excreted in human or animal breast milk. A risk to newborns/infants cannot be excluded and therefore HALAVEN must not be used during breast‑feeding (see section 4.3).</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>Testicular toxicity has been observed in rats and dogs (see section 5.3). Male patients should seek advice on conservation of sperm prior to treatment because of the possibility of irreversible infertility due to therapy with HALAVEN.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HALAVEN may cause adverse reactions such as tiredness and dizziness which may lead to minor or moderate influence on the ability to drive or use machines. Patients should be advised not to drive or use machines if they feel tired or dizzy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>&nbsp;</p><p>The most commonly reported adverse reactions related to HALAVEN, are bone marrow suppression manifested as neutropenia, leucopenia, anaemia, thrombocytopenia with associated infections. New onset or worsening of pre-existing peripheral neuropathy has also been reported. Gastrointestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, and stomatitis are among reported undesirable effects. Other undesirable effects include fatigue, alopecia, increased liver enzymes, sepsis and musculoskeletal pain syndrome.</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>Unless otherwise noted, the table shows the incidence rates of adverse reactions observed in breast cancer and soft tissue sarcoma patients who received the recommended dose in Phase 2 and Phase 3 studies.</p><p>&nbsp;</p><p>Frequency categories are defined as: very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000) and very rare (&lt;&nbsp;1/10,000).</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing frequency. Where Grade 3 or 4 reactions occurred, the actual total frequency and the frequency of Grade 3 or 4 reactions are given.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:643px"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Adverse Reactions &ndash; all Grades</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Very Common</strong></p><p><strong>(Frequency %)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(Frequency %)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(Frequency %)</strong></p></td><td style="vertical-align:top"><p><strong>Rare or not known</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Infections and infestations </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urinary tract infection (8.5%) (G3/4: 0.7%)</p><p>Pneumonia (1.6%) (G3/4: 1.0%)</p><p>Oral candidiasis</p><p>Oral herpes</p><p>Upper respiratory tract infection</p><p>Nasopharyngitis</p><p>Rhinitis</p><p>Herpes zoster</p></td><td style="vertical-align:top"><p>Sepsis (0.5%)</p><p>(G3/4: 0.5%)<sup>a</sup></p><p>Neutropenic sepsis</p><p>(0.2%) (G3/4: 0.2%)<sup>a</sup></p><p>Septic Shock (0.2%) (G3/4:0.2%)<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Neutropenia (53.6%) (G3/4: 46.0%)</p><p>Leukopenia (27.9%)</p><p>(G3/4: 17.0%)</p><p>Anaemia (21.8%) (G3/4: 3.0%)</p></td><td style="vertical-align:top"><p>Lymphopenia (5.7%) (G3/4: 2.1%)</p><p>Febrile neutropenia (4.5%) (G3/4: 4.4%)<sup>a</sup></p><p>Thrombocytopenia</p><p>&nbsp;(4.2%) (G3/4: 0.7%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><sup>*</sup>Disseminated intravascular coagulation<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Decreased appetite</p><p>&nbsp;(22.5%) (G3/4: 0.7%)<sup>d</sup></p></td><td style="vertical-align:top"><p>Hypokalaemia (6.8%) (G3/4: 2.0%)<br />Hypomagnesaemia</p><p>(2.8%) (G3/4: 0.3%)<br />Dehydration (2.8 %) (G3/4: 0.5%)<sup>d</sup></p><p>Hyperglycaemia</p><p>Hypophosphataemia</p><p>Hypocalcaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia</p><p>Depression</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Peripheral neuropathy<sup>c</sup> (35.9%) (G3/4: 7.3%)<br />Headache (17.5%) (G3/4: 0.7%)</p></td><td style="vertical-align:top"><p>Dysgeusia</p><p>Dizziness (9.0%) (G3/4: 0.4%)<sup>d</sup></p><p>Hypoaesthesia</p><p>Lethargy</p><p>Neurotoxicity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lacrimation increased</p><p>(5.8%) (G3/4: 0.1%)<sup>d</sup></p><p>Conjunctivitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p><p>Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hot flush</p><p>Pulmonary embolism (1.3%) (G3/4: 1.1%)<sup>a</sup></p></td><td style="vertical-align:top"><p>Deep vein thrombosis</p><p>Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>Dyspnoea (15.2%)<sup>a</sup> (G3/4: 3.5%)<sup>a</sup></p><p>Cough (15.0%)</p><p>(G3/4: 0.5%)<sup>d</sup></p></td><td style="vertical-align:top"><p>Oropharyngeal pain</p><p>Epistaxis</p><p>Rhinorrhoea</p></td><td style="vertical-align:top"><p>Interstitial lung disease (0.2%) (G3/4: 0.1%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Nausea (35.7%)</p><p>(G3/4: 1.1%)<sup>d</sup></p><p>Constipation (22.3%)</p><p>(G3/4: 0.7%)<sup>d</sup><br />Diarrhoea (18.7%) (G3/4: 0.8%)</p><p>Vomiting (18.1%) (G3/4: 1.0%)</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abdominal pain<br />Stomatitis (11.1%) (G3/4: 1.0%)<sup>d</sup></p><p>Dry mouth<br />Dyspepsia (6.5%) (G3/4: 0.3%)<sup>d</sup></p><p>Gastrooesophageal reflux disease</p><p>Abdominal distension</p></td><td style="vertical-align:top"><p>Mouth ulceration</p><p>Pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Aspartate aminotransferase increased (7.7%) (G3/4: 1.4%)<sup>d</sup></p><p>Alanine aminotransferase increased (7.6%) (G3/4: 1.9%)<sup>d</sup></p><p>Gamma glutamyl transferase increased (1.7%) (G3/4: 0.9%)<sup>d</sup></p><p>Hyperbilirubinaemia (1.4%) (G3/4: 0.4%)</p></td><td style="vertical-align:top"><p>Hepatotoxicity (0.8%) (G3/4: 0.6%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>Rash (4.9%) (G3/4: 0.1%)</p><p>Pruritus (3.9%)</p><p>(G3/4: 0.1%)<sup>d</sup></p><p>Nail disorder</p><p>Night sweats</p><p>Dry skin</p><p>Erythema</p><p>Hyperhidrosis</p><p>Palmar plantar erythrodysaesthesia (1.0%) (G3/4: 0.1%)<sup>d</sup></p></td><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top"><p><sup>**</sup>Stevens-Johnson syndrome/ Toxic epidermal necrolysis<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Arthralgia and myalgia (20.4%) (G3/4: 1.0%)</p><p>Back pain (12.8%) (G3/4: 1.5%)</p><p>Pain in extremity (10.0%) (G3/4: 0.7%)<sup>d</sup></p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bone pain (6.7%) (G3/4: 1.2%)</p><p>Muscle spasms (5.3%) (G3/4: 0.1%)<sup>d</sup></p><p>Musculoskeletal pain Musculoskeletal chest pain</p><p>Muscular weakness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dysuria</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haematuria</p><p>Proteinuria</p><p>Renal failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Fatigue/Asthenia (53.2%) (G3/4&nbsp;: 7.7%)<br />Pyrexia (21.8%)</p><p>(G3/4: 0.7%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>Mucosal Inflammation (6.4%) (G3/4: 0.9%)<sup>d</sup></p><p>Peripheral oedema</p><p>Pain</p><p>Chills</p><p>Chest pain</p><p>Influenza like illness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Weight decreased (11.4%) (G3/4: 0.4%)<sup>d</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Includes Grade 5 events.</p><p><sup>b &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>From spontaneous reporting</p><p><sup>c &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Includes preferred terms of peripheral neuropathy, peripheral motor neuropathy, polyneuropathy, paraesthesia, peripheral sensory neuropathy, peripheral sensorimotor neuropathy and demyelinating polyneuropathy</p><p><sup>d &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>No Grade 4 events</p><p><sup>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Rare</p><p><sup>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Frequency not known</p><p>&nbsp;</p><p>Overall, the safety profiles in the breast cancer and soft tissue sarcoma patient populations were similar.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Neutropenia</u></em></p><p>The neutropenia observed was reversible and not cumulative; the mean time to nadir was 13 days and the mean time to recovery from severe neutropenia (&lt;&nbsp;0.5&nbsp;x&nbsp;10<sup>9</sup>/l) was 8 days.</p><p>Neutrophil counts of &lt;&nbsp;0.5&nbsp;x&nbsp;10<sup>9</sup>/l that lasted for more than 7 days occurred in 13% of breast cancer patients treated with eribulin in the EMBRACE study.</p><p>Neutropenia was reported as a Treatment Emergent Adverse Event (TEAE) in 151/404 (37.4% for all grades) in the sarcoma population, compared with 902/1559 (57.9% for all grades) in the breast cancer population. The combined grouped TEAE and neutrophil laboratory abnormality frequencies were 307/404 (76.0%) and 1314/1559 (84.3%), respectively. The median duration of treatment was 12.0 weeks for sarcoma patients and 15.9 weeks for breast cancer patients.</p><p>Fatal cases of febrile neutropenia, neutropenic sepsis, sepsis and septic shock have been reported. Out of 1963 breast cancer and soft tissue sarcoma patients who received eribulin at the recommended dose in clinical trials there was one fatal event each of neutropenic sepsis (0.1%) and febrile neutropenia (0.1%). In addition there were 3 fatal events of sepsis (0.2%) and one of septic shock (0.1%).</p><p>Severe neutropenia may be managed by the use of G-CSF or equivalent at the physician&rsquo;s discretion in accordance with relevant guidelines. 18% and 13% of eribulin treated patients received G-CSF in the two phase 3 breast cancer studies (Studies 305 and 301, respectively). In the phase 3 sarcoma study (Study 309), 26% of the eribulin treated patients received G-CSF.</p><p>Neutropenia resulted in discontinuation in &lt;&nbsp;1% of patients receiving eribulin.<em> </em></p><p><em>&nbsp;</em></p><p><em><u>Disseminated intravascular coagulation</u></em></p><p>Cases of disseminated intravascular coagulation have been reported, typically in association with neutropenia and/or sepsis.</p><p>&nbsp;</p><p><em><u>Peripheral neuropathy</u></em></p><p>In the 1559 breast cancer patients the most common adverse reaction resulting in discontinuation of treatment with eribulin was peripheral neuropathy (3.4%). The median time to Grade 2 peripheral neuropathy was 12.6 weeks (post 4 cycles). Out of the 404 sarcoma patients, 2 patients discontinued treatment with eribulin due to peripheral neuropathy. The median time to Grade 2 peripheral neuropathy was 18.4 weeks.</p><p>Development of Grade 3 or 4 peripheral neuropathy occurred in 7.4% of breast cancer patients and 3.5% of sarcoma patients. In clinical trials, patients with pre-existing neuropathy were as likely to develop new or worsening symptoms as those who entered the study without the condition.</p><p>In breast cancer patients with pre-existing Grade 1 or 2 peripheral neuropathy the frequency of treatment-emergent Grade&nbsp;3 peripheral neuropathy was 14%.</p><p><u>&nbsp;</u></p><p><em><u>Hepatotoxicity</u></em></p><p>In some patients with normal/abnormal liver enzymes prior treatment with eribulin, increased levels of liver enzymes have been reported with initiation of eribulin treatment. Such elevations appeared to have occurred early with eribulin treatment in cycle 1 &ndash; 2 for the majority of these patients and whilst thought likely to be a phenomenon of adaptation to eribulin treatment by the liver and not a sign of significant liver toxicity in most patients, hepatotoxicity has also been reported.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Elderly population</u></em></p><p>Of the 1559 breast cancer patients treated with the recommended dose of eribulin, 283 patients (18.2%) were &ge;&nbsp;65 years of age. In the 404 sarcoma patient population, 90 patients (22.3%) treated with eribulin were &ge; 65 years of age. The safety profile of eribulin in elderly patients (&ge;&nbsp;65 years of age) was similar to that of patients &lt;65 years of age except for asthenia/fatigue which showed an increasing trend with age. No dose adjustments are recommended for the elderly population.</p><p><u>&nbsp;</u></p><p><em><u>Patients with hepatic impairment</u></em></p><p>Patients with ALT or AST &gt; 3&nbsp;x&nbsp;ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia. Although data are limited, patients with bilirubin &gt; 1.5&nbsp;x&nbsp;ULN also have a higher incidence of Grade 4 neutropenia and febrile neutropenia (see also sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong><em>&bull; Saudi Arabia</em></strong></p><p><strong><em>&nbsp;</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Center (NPC)</p><p>Fax: + (966-11) 2057662</p><p>Call NPC at: + (966-11) 2038222, Exts: 2317-2356-2340</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>&bull; Other GCC States:</em></strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_1" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;margin-left:5.4pt;margin-top:7.85pt;
 width:397.05pt;height:21.4pt;z-index:251664896;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" strokeweight=".5pt"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In one case of overdose the patient inadvertently received 7.6&nbsp;mg of eribulin (approximately 4 times the planned dose) and subsequently developed a hypersensitivity reaction (Grade 3) on Day 3 and neutropenia (Grade 3) on Day 7. Both adverse reactions resolved with supportive care.</p><p>&nbsp;</p><p>There is no known antidote for eribulin overdose. In the event of an overdose, the patient should be closely monitored. Management of overdose should include supportive medical interventions to treat the presenting clinical manifestations.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other antineoplastic agents, ATC code: L01XX41</p><p>&nbsp;</p><p>Eribulin mesilate is a microtubule dynamics inhibitor belonging to the halichondrin class of antineoplastic agents. It is a structurally simplified synthetic analogue of halichondrin B, a natural product isolated from the marine sponge <em>Halichondria okadai</em>.</p><p>&nbsp;</p><p>Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into non-productive aggregates. Eribulin exerts its effects via a tubulin-based antimitotic mechanism leading to G<sub>2</sub>/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged and irreversible mitotic blockage.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy</u></p><p><u>&nbsp;</u></p><p><u>Breast cancer</u></p><p>&nbsp;</p><p>The efficacy of HALAVEN in breast cancer is primarily supported by two randomized Phase 3 comparative studies.</p><p>The 762 patients in the pivotal Phase 3 EMBRACE study (Study 305) had locally recurrent or metastatic breast cancer, and had previously received at least two and a maximum of five chemotherapy regimens, including an anthracycline and a taxane (unless contraindicated). Patients must have progressed within 6 months of their last chemotherapeutic regimen. The HER2 status of the patients was: 16.1% positive, 74.2% negative and 9.7% unknown, whilst 18.9% of patients were triple negative. They were randomized 2:1 to receive either HALAVEN, or treatment of physician&rsquo;s choice (TPC), which consisted of 97% chemotherapy (26% vinorelbine, 18%&nbsp;gemcitabine, 18% capecitabine, 16% taxane, 9% anthracycline, 10% other chemotherapy), or 3% hormonal therapy.</p><p>The study met its primary endpoint with an overall survival (OS) result that was statistically significantly better in the eribulin group compared to TPC at 55% of events.</p><p>This result was confirmed with an updated overall survival analysis carried out at 77% of events.</p><p><strong>&nbsp;</strong></p><p><strong>Study 305 - Updated Overall Survival ( ITT Population)</strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_12" o:spid="_x0000_s1029"
 type="#_x0000_t202" style='position:absolute;margin-left:226.4pt;margin-top:9.1pt;
 width:233.15pt;height:151.35pt;z-index:251653632;visibility:visible'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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==
" filled="f" stroked="f">
 <v:textbox inset=",7.2pt,,7.2pt"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="805" height="488" vspace="0" hspace="0" border="0" style="width:805px;height:488px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>By independent review, the median progression free survival (PFS) was 3.7 months for eribulin compared to 2.2 months for the TPC arm (HR 0.865, 95% CI: 0.714, 1.048, p=0.137). In response evaluable patients, the objective response rate by the RECIST criteria was 12.2% (95% CI: 9.4%, 15.5%) by independent review for the eribulin arm compared to 4.7% (95% CI: 2.3%, 8.4%) for the TPC arm.</p><p>&nbsp;</p><p>The positive effect on OS was seen in both taxane-refractory and non-refractory groups of patients . In the OS update, the HR for eribulin versus TPC was 0.90 (95% CI: 0.71, 1.14) in favour of eribulin for taxane-refractory patients and 0.73 (95% CI: 0.56, 0.96) for patients not taxane-refractory.</p><p>&nbsp;</p><p>The positive effect on OS was seen both in capecitabine-na&iuml;ve and in capecitabine pre-treated patient groups. The updated OS analysis showed a survival benefit for the eribulin group compared to TPC both in capecitabine pre-treated patients with a HR of 0.787 (95% CI: 0.645, 0.961), and for the capecitabine-na&iuml;ve patients with a corresponding HR of 0.865 (95% CI: 0.606, 1.233).</p><p>&nbsp;</p><p>The second Phase 3 study in earlier line metastatic breast cancer, Study 301, was an open-label, randomized, study in patients (n=1102) with locally advanced or metastatic breast cancer to investigate the efficacy of HALAVEN monotherapy compared to capecitabine monotherapy in terms of OS and PFS as co-primary endpoint. Patients had previously received up to three prior chemotherapy regimens, including both an anthracycline and a taxane and a maximum of two for advanced disease, with the percentage who had received 0, 1 or 2 prior chemotherapy treatments for metastatic breast cancer being 20.0%, 52.0% or 27.2% respectively. The HER2 status of the patients was: 15.3% positive, 68.5% negative and 16.2% unknown, whilst 25.8% of patients were triple negative.</p><p><strong>&nbsp;</strong></p><p><strong>Study 301 - Overall Survival (ITT Population)</strong><u> </u></p><p><img src="data:image/png;base64,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" alt="" width="821" height="512" vspace="0" hspace="0" border="0" style="width:821px;height:512px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p><span style="text-align:unset">Progression free survival assessed by independent review was similar between eribulin and capecitabine with medians of 4.1 months vs 4.2 months (HR 1.08; [95% CI: 0.932, 1.250]) respectively. Objective response rate as assessed by independent review was also similar between eribulin and capecitabine; 11.0% (95% CI: 8.5, 13.9) in the eribulin group and 11.5% (95% CI: 8.9, 14.5) in the capecitabine group.</span></p><p>&nbsp;</p><p>The overall survival in patients in HER2 negative and HER2 positive patients in the eribulin and control groups in Study 305 and Study 301 is shown below:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:558px"><tbody><tr><td rowspan="2"><p><strong>Efficacy Parameter</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Study 305 Updated Overall Survival ITT Population</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>HER2 Negative </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>HER2 Positive </strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>HALAVEN</strong></p><p><strong>(n = 373)</strong></p></td><td style="vertical-align:top"><p><strong>TPC</strong></p><p><strong>(n = 192)</strong></p></td><td style="vertical-align:top"><p><strong>HALAVEN</strong></p><p><strong>(n = 83)</strong></p></td><td style="vertical-align:top"><p><strong>TPC</strong></p><p><strong>(n = 40)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of Events</p></td><td><p>285</p></td><td><p>151</p></td><td><p>66</p></td><td><p>37</p></td></tr><tr><td style="vertical-align:top"><p>Median months</p></td><td style="vertical-align:top"><p>13.4</p></td><td style="vertical-align:top"><p>10.5</p></td><td style="vertical-align:top"><p>11.8</p></td><td style="vertical-align:top"><p>8.9</p></td></tr><tr><td style="vertical-align:top"><p>Hazard Ratio (95% CI)</p></td><td colspan="2"><p>0.849 (0.695, 1.036)</p></td><td colspan="2"><p>0.594 (0.389, 0.907)</p></td></tr><tr><td style="vertical-align:top"><p>p-value (log rank)</p></td><td colspan="2"><p>0.106</p></td><td colspan="2"><p>0.015</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:558px"><tbody><tr><td rowspan="2"><p><strong>Efficacy Parameter</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Study 301 Overall Survival ITT Population</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>HER2 Negative </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>HER2 Positive </strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>HALAVEN</strong></p><p><strong>(n = 375)</strong></p></td><td style="vertical-align:top"><p><strong>Capecitabine</strong></p><p><strong>(n = 380)</strong></p></td><td style="vertical-align:top"><p><strong>HALAVEN</strong></p><p><strong>(n = 86)</strong></p></td><td style="vertical-align:top"><p><strong>Capecitabine</strong></p><p><strong>(n = 83)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of Events</p></td><td><p>296</p></td><td><p>316</p></td><td><p>73</p></td><td><p>73</p></td></tr><tr><td style="vertical-align:top"><p>Median months</p></td><td style="vertical-align:top"><p>15.9</p></td><td style="vertical-align:top"><p>13.5</p></td><td style="vertical-align:top"><p>14.3</p></td><td style="vertical-align:top"><p>17.1</p></td></tr><tr><td style="vertical-align:top"><p>Hazard Ratio (95% CI)</p></td><td colspan="2"><p>0.838 (0.715, 0.983)</p></td><td colspan="2"><p>0.965 (0.688, 1.355)</p></td></tr><tr><td style="vertical-align:top"><p>p-value (log rank)</p></td><td colspan="2"><p>0.030</p></td><td colspan="2"><p>0.837<sup> </sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Note: Concomitant anti-HER2 therapy was not included in Study 305 and Study 301.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Liposarcoma</u></p><p>In liposarcoma the efficacy of eribulin is supported by the pivotal Phase 3 sarcoma study (Study 309). The patients in this study (n=452) had locally recurrent, inoperable and/or metastatic soft tissue sarcoma of one of two subtypes &ndash; leiomyosarcoma or liposarcoma. Patients had received at least two prior chemotherapy regimens, one of which must have been an anthracycline (unless contraindicated).</p><p>Patients must have progressed within 6 months of their last chemotherapeutic regimen. They were randomized 1:1 to receive either eribulin 1.23 mg/m<sup>2</sup> on days 1 and 8 of a 21 day cycle or dacarbazine 850 mg/m<sup>2</sup>, 1000 mg/m<sup>2</sup> or 1200 mg/m<sup>2</sup> (dose determined by the investigator prior to randomization), every 21 days.</p><p>In Study 309, a statistically significant improvement in OS was observed in patients randomized to the eribulin arm compared to the control arm. This translated into a 2 month improvement in median OS (13.5 months for eribulin treated patients vs. 11.5 months for dacarbazine treated patients). There was no significant difference in progression-free survival or overall response rate between the treatment arms in the overall population.</p><p>Treatment effects of eribulin were limited to patients with liposarcoma (45% dedifferentiated, 37% myxoid/round cell and 18% pleomorphic in Study 309) based on pre-planned subgroup analyses of OS and PFS. There was no difference in efficacy between eribulin and dacarbazine in patients with advanced or metastatic leiomyosarcoma.</p><table border="1" cellspacing="0" cellpadding="0" style="width:635px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Study 309 </strong></p><p><strong>Liposarcoma Subgroup</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study 309</strong></p><p><strong>Leiomyosarcoma Subgroup</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study 309</strong></p><p><strong>ITT Population</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HALAVEN</strong></p><p><strong>(n=71)</strong></p></td><td style="vertical-align:top"><p><strong>Dacarbazine</strong></p><p><strong>(n=72)</strong></p></td><td style="vertical-align:top"><p><strong>HALAVEN</strong></p><p><strong>(n=157)</strong></p></td><td style="vertical-align:top"><p><strong>Dacarbazine</strong></p><p><strong>(n=152)</strong></p></td><td style="vertical-align:top"><p><strong>HALAVEN</strong></p><p><strong>&nbsp;(n=228)</strong></p></td><td style="vertical-align:top"><p><strong>Dacarbazine</strong></p><p><strong>&nbsp;(n=224)</strong></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Overall survival</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;Number of Events</p></td><td><p>52</p></td><td><p>63</p></td><td><p>124</p></td><td><p>118</p></td><td><p>176</p></td><td><p>181</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Median months</p></td><td><p>15.6</p></td><td><p>8.4</p></td><td><p>12.7</p></td><td><p>13.0</p></td><td><p>13.5</p></td><td><p>11.5</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Hazard Ratio (95% CI)</p></td><td colspan="2"><p>0.511 (0.346, 0.753)</p></td><td colspan="2"><p>0.927 (0.714, 1.203)</p></td><td colspan="2"><p>0.768 (0.618, 0.954)</p></td></tr><tr><td><p>&nbsp;Nominal p-value</p></td><td colspan="2"><p>0.0006</p></td><td colspan="2"><p>0.5730</p></td><td colspan="2"><p>0.0169</p></td></tr><tr><td colspan="7"><p><strong>Progression-free survival</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;Number of Events</p></td><td><p>57</p></td><td><p>59</p></td><td><p>140</p></td><td><p>129</p></td><td><p>197</p></td><td><p>188</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;Median months</p></td><td><p>2.9</p></td><td><p>1.7</p></td><td><p>2.2</p></td><td><p>2.6</p></td><td><p>2.6</p></td><td><p>2.6</p></td></tr><tr><td style="vertical-align:top"><p>Hazard Ratio (95% CI)</p></td><td colspan="2"><p>0.521 (0.346, 0.784)</p></td><td colspan="2"><p>1.072 (0.835, 1.375)</p></td><td colspan="2"><p>0.877 (0.710, 1.085)</p></td></tr><tr><td style="vertical-align:top"><p>Nominal p-value</p></td><td colspan="2"><p>0.0015</p></td><td colspan="2"><p>0.5848</p></td><td colspan="2"><p>0.2287</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>Study 309 - Overall Survival in the Liposarcoma Subgroup</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="824" height="506" vspace="0" hspace="0" border="0" style="width:824px;height:506px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p><strong>Study 309 &ndash; Progression Free Survival in the Liposarcoma Subgroup</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAA1EAAAHhCAYAAACP0DT2AAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAEnQAABJ0Ad5mH3gAAHkqSURBVHhe7d0HuFTVvfdxU27aTe4bU25MrlERBClSrFhTjLEkGlvUqKAICIqAooAdW1RiCyqC3RgVKwKCCthBsKCCxkaxgNhQikjRvO9d7/z+zP+42DNzzplzZs6Z8v08z3pm7zV72j777Fm/WXuvvUEAEv7f//t/dnvccceF//mf/7Hp//t//6/dAgAAANWOEIUMhCgAAAAgN0IUMhCiAAAAgNwIUchAiAIAAAByI0QhAyEKAAAAyI0QhQyEKAAAACA3QhQyEKIAAACA3AhRyECIAgAAAHIjRCEDIQoAAADIjRCFDIQoAAAAIDdCFDIQogAAAIDcCFHIQIgCAAAAciNEIQMhCgAAAMiNEIUMhCgAAAAgN0IUMhCiAAAAgNwIUWVGYebf//53em7dvEKPbv/3f/83XbvO6tWrrc5DUX0VKkT5+/Fbfw5/r3qd5HuuTfL5AAAAgOZAiCozX3zxhd3OnTs33HDDDTYdh4rrr78+DBo0KHz44Yc2r8CSbwAqRIjS8l9++aUFPj2fbvU+PUBl4+81W/HH67nWrl2bfgQAAADQ9AhRZWjFihXhW9/6Vjj44INt3kPJJZdcEv77v/87/OUvfwk//vGPrU4UZvLR2BDljy+GfN4HAAAAUAyEqDLz8ccfh69//euhVatW4bDDDrM6DxY/+MEPwuOPP27T3/3ud8Ps2bNt2nuv8tWvX78G90Q988wzFuoGDx4cTj755HDttdeGESNGhEsvvTQcddRR4fLLLw9///vfw0UXXRR69+4djjnmmNCrV6/Qo0ePrKVnz57hyCOPDOecc076FQAAAIDmQYgqM+qFevvtt8OVV14Z9ttvP6vznp8NNtggfPDBBzbdpUuXcPPNN9t0rp6o5cuXh1mzZoWXXnqpprz88sthzpw5Yf78+RZsNttsM1s2Pg+rPh555JFwwgknhD/84Q9hm222CUOGDAkDBw4Mffv2DS1atLD5s846ywJWmzZtQrt27ULr1q1Dp06dbLp9+/ahbdu2oUOHDqFz585Wv+2224bDDz88/Qrrgp164ZJF9Jl9GgAAACgkQlSZ8WAwbNiwcOCBB9q0U4jyc6G6du0arrnmGptO8ue4//777TG5yk9/+lMLMpJPT5Sef8GCBeGpp54KU6dOtUClgDZz5szw7LPP2uvOmDEjDB06NJx77rnh4YcfDmPHjg1TpkwJDzzwgJUJEybUlPHjx4e7777bwlX37t3tNTxAKUDGRWHPAx8hCgAAAMVAiCozHgx0WJv3RLlvf/vb4a233rLpTTbZJNx+++02nexF0nOofPrpp2HMmDEWULwozIwbNy5MnDjRzrlSr5F4b1d91De83HTTTeHee+9Nz9Vu1apV1jvVrVu3dE3d8u09AwAAAOqDEFWmzj777LDvvvtaYNH5R9KxY0c770jUk/TOO+/YdPJwPj1G50nVFXYGDBgQNt544/Rc/el51VOkovAVH3bnYUwBRz1ROidKhxXqvo8++igsW7YsLFq0yN7fZ599Ft5//32rW7hwofWK6RBDhT8d0vjKK6+EN954I7z55ps1xed1WCIAAABQDISoMuODRFxwwQU24IIOlfvJT35idQpTP/rRj2xQCQ3SIB5ikpKhJuZ1xx9/fM3AEtmWq42W99dQEX89D1c6H+rUU08N5513nt2v6VNOOcVeV+d26ZA/DTqh5TRIxU477WSHMWq5Pn362LlSOmdK50t5UZ3OB1PAdP75s60HAAAAIF+EqDKjIKCiw9s+//xzm166dGn63nWDRajXRjy0eIipLw9Mjb3Ybjb+/nUh4DPOOMOKBpiQ008/3aYVABcvXhyee+45u+aVQpNG89t9991tGT3mtNNOC7/73e9s4Io999wz7LXXXmHvvfcO++yzj4UoP19Mn0XXldKtfy4AAACgMQhRZUYBJB44wcONhxPn9yk4xPX1UcwQJf78OlxPhxp675pPK2D5tAKQpv0zKzAqSGl0QvHHOoXLrbfeOmPQDck3TAIAAADZEKLKjMKEShwu/FZBx6dVFBr8/nwUM0TpufWe1qxZUzMvqov5+xe9tqa1rEKSDu8bPny4Tes8qpiW0Sh+BxxwQJg2bZoN4f7oo4/W9M4BAAAAjUWIKjMeLLL1qsR1uabro5ghqrb3ovu8OJ/2kKXgpEP5zjzzTLvWlM6fUo+WU8+UBqDQtal0vpRG9Nt0001tFEIAAACgEAhRyFDMENVQClF6DxqZ78QTT7QQpaJeKR3+5xSydO7UIYccEg466CAbBl49U7r2FAAAAFAIhChkKMUQle31r7jiinDEEUfUHPqXbRld90rXzNIFewEAAIBCIEQhQ6n2RCko+Tlf8WF/uvWeKr13TauILui72Wab2YWEAQAAgEIgRCFDKYaobC699NLQr1+/mvcr8bTcfPPNFqLuu+++dA0AAADQOIQoZCiXEKVrRw0YMIAQBQAAgCZFiEKGcglRkydPtnBEiAIAAEBTIkQhQzmEKJ0HNWfOnPDYY4+la9bVJd+nQlSLFi3ChAkT0jVfDaUOAAAANAQhChnKpSfqoosuCv379w+PP/54WLZsmdUl3+eNN94YOnfuHA4++GA7f0oDU2iZUvw8AAAAKA+EKGQolxD117/+1S68q/e5YMGCdO36rrvuurDRRhuFXXbZJey4447pWgAAAKDhCFHIUOohyg/Fu+eee8IFF1wQBg8eHN58802rS3r77bftGlG///3vw6677mqfTY9XjxQAAADQEIQoZCiHnii/DtS4cePskL558+bZvEue8/SrX/0q7LbbbjbNOVEAAABoDEIUMpRDiPL3eNttt9kw50899VSYP39+ePXVV+1W4t4mBSgPUeKPBwAAAPJFiEKGUg9R6kXy93j77bfbeVGnnnpqGDhwYBg0aFC48sor7b4vvvjCboUQBQAAgEIhRCFDOYQoPxxv4sSJNkqfisJTHKLiQ/aSIYrD+QAAANBQhChkKPUQpfOhFIKS7+mDDz4IJ554Yhg9erTNx/fvvvvuNrCEqJ6BJQAAANBQhChkKPUQlZTr0DzvsdL9O++8s/VE+fWkAAAAgIYiRCFDuYUov4Cu+Kh9+gweolT22muvsMMOO4Rtt92WIAUAAIBGIUQhQ7mFqDg4xYfqKTyJBphQT1SXLl3skD7Nl/LnAQAAQGkjRCFDuYUof2+LFy8Offr0CSNGjLB58c8ie+65Z9huu+3C2rVr0zUAAABA/ghRyFCOPVF6z0uXLrXR+c4+++xw6623hnfeeccGmtB1pJ555pnwxz/+Meyyyy5hjz32CJdcckn60QAAAEB+CFHIUK49UQsXLgx9+/YNQ4cOtRH65s2bF0444QSbnzZtWvjd734XOnToEHbcccdw1lln2WMAAACAfBGikKHcQtTq1avt/elcJx3Sp/LRRx/ZOVFPPfVU6N27d5g0aVJ49dVXw0033RRat25NiAIAAECDEaKQodxClPggEklr1qwJb731VliyZInNP/fcc6Fdu3Z2yJ/4oYC5Hg8AAAAkEaKQoRxDVC7qnXr33XfDihUrbF7nRm2xxRZh2LBhNu8BihAFAACA+iJEIUMlhSidF9WtW7cwduxYm58+fXpo06ZNOOWUU8Knn35KTxQAAADyRohChkoKUW+88Ubo16+fnRMlTz/9tA0uoYvu6vMJPVEAAADIByEKGSopRGmY8169eoUJEybY/KOPPmoX3FWIGjx4sNWJf2YAAACgLoQoZKikEKXzoXStqKlTp6ZrQpg9e3bNIX2OEAUAAID6IkQhQyWFqDgc+WfQUOca5pwQBQAAgIYgRCFDJYUoXTNq1KhR4fnnn0/XhPDaa6+FFi1acDgfAAAAGoQQhQyVFKLmzp0bjj322DB+/Ph0zbq6Vq1aEaIAAADQIIQoZKikELVgwYLQp0+f8NBDD6VrCFEAAABoHEIUMlRaT1T37t3DuHHj0jWEKAAAADQOIQoZKilELV26NDz88MN2HpQjRAEAAKAxCFHIUEkhKhtCFAAAABqDEIUMlRSiFi1aZNeJ4pwoAAAAFAohChkqKUTNmzfPPscDDzyQrvkqRA0ZMiRdQ4gCAABA/RGikKHSQtTxxx8fHnzwwXRNCG+++aZdbHfAgAHhf//3f63ObwEAAIC6EKKQoZJC1Ntvvx2OOeaYMGHChHRNCK+++mrYcsstw9Zbbx2uv/76dC0AAABQP4QoZKikELVmzZrw+eefW/HeJoWozp07Wxk9erTV0RMFAACA+iJEIUMlhajly5eHF154Ibz33nvrfYY77rgjtGjRIlx77bU2T4gCAABAfRGikKGSQtT8+fPD0UcfXTOwxBdffGG3kyZNCptuumm4+eabbZ4QBQAAgPoiRCFDpYWo3r1715wT5Z9NoWqzzTarOSfK6wEAAIC6EKKQoZJClA8s4T1R/jkIUQAAAGgoQhQyVFqIGjZsWHj44YdtnhAFAACAxiJElZlkY//f//63FT+nx8/5cdnCgZb1khQ/l66vVO4hKqbP4OuDEAUAAICGIkSVoSeeeCJss802YcSIETbvgejLL7+0+auvvjp06dIl3HrrrTa/du1au40pLClw6XEKEF78PqmEnqiFCxeG888/Pzz99NM275/toYceIkQBAACgQQhRZebjjz8OG2ywQRgzZozdjhs3zuq990gB6pvf/GaYPHmy3R9fZNZpWYWi+NaLeKA44YQTyj5EzZ49O/Tp0ydcfPHFNedFCSEKAAAADUWIKjMjR44M++yzT830b3/7W5v2AHTUUUeFU045xaY1tPfQoUNtOlbfwKDnqYQQNWjQoHD66aeHk046KV27bohzhagbbrjB5glRAAAAqC9CVJlR71C/fv1sWj0rv/jFL2xaIUpBQIf0ffe73w3bb799+K//+q+aw9diHoimTJlivVU//elPa8rPfvazsNFGG4WNN944/PKXvwxt2rSxZT2klZt33nkn3H///RYI40A5ceJEu07U6NGjbb5cPx8AAACaHiGqzOiaRzpXSR588MHw4x//2KY9LP3tb38L7dq1s4DUqlWrcOONN1p9zJdVL81ee+0VDjnkkJpy8MEHhz//+c+hR48eYdtttw2tW7e2ZcvdfffdZ4c2eoBUT1SLFi1qLrZLTxQAAADqixBVZs4555zwl7/8xabvvPPO0KlTJ5t26k2aPn26Tet8KQWqpPg8qNoMHjzYeqSkXHtqkoch+ufQkOdbbbVV6Nmzp83TEwUAAID6IkSVmccff9wO05Odd945nH322TZ97bXX2u3uu+9eEwzUq3TggQfadMwDlHqkdKugoZ4YL95TpR4vP1ywXHtq9L51iOP48ePtED6neQXMli1b2mAdAAAAQH0RosqQDrfTeUvqhdLw5atXr7Zzm5YtWxaWLl1qh/H9/Oc/t56WXAHBg1Q87fMemPr27VsR14nSOtLgEieffHK6JoRp06ZZCN16663DypUr07UAAABA3QhRZcaDzocffmi3opCQDDkKVC7fAOQhqhKuEyVaP6eddloYNmyYzftn0XlfOi8qXlcAAABAXQhROShADB8+vKaUCh1q5yHHpxWsdOvT4vMKDH54Xn3pcVKpIco/n84ta9++fc08AAAAUB+EqFrokC+NUKdD5UqFwoyCkoKRB6Q4LHl9fJ9u81FpIWrNmjXhxBNPXO9wPunevXvYbrvtsl5LCwAAAMiFEFWHBQsWlFSIcgpS2YrLNV0flRSiPFA+99xz4cUXX0zXrrP33nuHHXfcMXTu3DldAwAAANSNEJWiHqfalGKIKqZKClH6LMkQ6fO33XZb2GGHHWyACQAAAKC+CFEptYWkTz75hBCVUs6H8+mcKF2E+KqrrkrXfBWk9txzz9C1a1ebBgAAAOqDEJWikFRXqSaVFKIUlnROmA8s8Y9//MOuGyVffPFF2GWXXey8KAAAAKC+CFEpCknqkchVCFHlHaLUE6XPctZZZ9nFif3z6fZXv/oVh/MBAAAgL4SolLpCEiGqfEOUj1b4wgsv2Oh8Z555ZvqedZ+JEAUAAIB8EaLqoZSuE9UUKilE6X37e584cWKYMmWKTauOnigAAAA0BCGqFhpUQkGCnqjyDVF+TpTMnTs3LF68uOb6WYQoAAAANAQhKotJkyaFQw891MKTl2pSSSFKn8VD1LHHHmvnRTl9JkIUAAAA8kWIStNFdXXYXsuWLdcLTwwsUd4hSiPx+XDmClF//etfbVQ+oScKAAAADUGISvGg5MWDlIKVcE5UeR/O559nzpw54c0337Rp1RGiAAAA0BCEqBQ/70mH8OlQPtF8taqkEOVhSfS3nTZtmk0LIQoAAAANQYhK0yASo0ePtl4nNbTjEBU3vKtBJYUovW//PP369bOL7k6dOtWuHaVeKkIUAAAA8kWIykKhSQFCoUqH9FVbr1Qlhaj4cL7+/fvbxXZ79uwZli5danWEKAAAAOSLEFUL9U75KH3VpNJ6otyNN94YzjnnHAtTS5YssTpCFAAAAPJFiKqDghQDS1RGT5RMmDAhnHnmmWHVqlU2T4gCAABAvghRKRqdT2EJ61RSiErS8OYrV660aX1OQhQAAADyRYhK0eF6BKmvVHKIGjlyZOjWrVv4/PPPbZ4QBQAAgHwRolIUohSgxowZY4NJ+DDn1aqSQ9QNN9wQjj766PDvf//b5nfbbTdCFAAAAPJCiMpCI/IpTKnMnj07XVs9KjlEzZs3L0yfPr3mXCmFqB133DF97zqV8lkBAABQHISoLDxEbbvtttZLpdtqUqkhSp/rxRdfDOPGjUvXrDsfbptttrFp9U4lB6IAAAAAkghRKWpIiw7n8yHNvWy44Ybh9NNPt/urRSX3ROmcqN69e4fJkyeHWbNmhd///vfht7/9bfredaP5ffnll+k5AAAAIBMhKsXDUhyeFCCq9dyoSg5Ro0aNCqeeemoYMGCA3R5yyCGhc+fONi0avQ8AAACoDSEqxYOTeqTUG1Xto/RVcoh68MEHw0033RT+/ve/24V3999//7DddttZD6Tos3NOFAAAAGpDiEpRgFJ4wjqVGqJ0qJ6bMWNGuPzyy+3vrnOijjzyyPQ9lRMYAQAAUByEqJRp06alpyCVGqL0uXS+k38+Wb16dWjbtq0Ne+4IUQAAAKgNISpFPVG1qev+SlOpIcpH39PtkiVLwqJFi8LChQtDmzZtwlFHHZVeihAFAACA2hGiUvx8qFyFEFU5PVH+2aZOnWqj9M2cOTO0b9+eEAUAAIB6I0SlKCTVVapJpYYo8c/x2GOPhX79+oUXXnghdOjQgRAFAACAeiNEpSgk6byoXIUQVZkh6oQTTiBEAQAAIG+EqJThw4enp7Kr6/5KUw0h6tFHH63pidpqq61Cr169rB4AAACoCyEqRT1NCxYsSM+hUkOUfy7ROVF9+vQJzz77bOjYsWP41a9+FXr06BF69uwZunXrZj1T9S0HHnhgePvtt9PPDAAAgEpHiEpRiNIAEpMmTUrXVLdKDVE+Mp8+3xdffGGf6aOPPgqbbbZZ6Ny5sw0wsfnmm4d27dqFVq1ahS222KLO0qVLFxsife7cuelXAQAAQKUjRKUoQIl6o0aPHm1l9uzZVleNqiFE6VbWrFkTxo4dGyZOnGghesqUKeGBBx4IDz/8cHjooYdqLU8++aT1WulwwEruiWrZsqX90OA/NogOcfU6lWRPri5irPokbVPx4+qi5f01Y9nek/jrqowcObJmOln0/uNl40N29VniZQEAAJJoIeSgASXUsFKg+uSTT9K11aFSQ5R/LtHhfDp877nnnkvXNMzxxx8fWrRo0eAQpWBXDrQtJM8N1P+Iwkw2HpYUVJJUly0YZeNhKdvhtrkClt6n3ptLPl7T8WfRc2iZ+DGi5wcAAMiGEJWFGnmHHnqoNay8VJNKDVH6DB5a1NM0ZMiQcO6554bTTjstrFy50urzpRClnqhXXnnFDhFUz9bq1asziuo/++wzex3NL1261N5LHOxKWT4hykNKrpBT3xCl5fw1kq8t3mOUlAxuWiZbCHP+2ZLPRYgCAAC5EKJS1HjS4XtqNG244YY270VhqtrOlarUEKXQ8uWXX9r0fffdFwYMGBBOOeWUMHjw4PD5559bfb769u0bdthhBzs3aptttrHbbEXnXClsadlOnTrZYBbvvvtu+llKnweNWK4QpeUUWnR/MphIfUOUhxg9X67lVR+/L71ubSFKt8nP4a+j54pfx+sBAACSCFEpcWhS2Xbbba0hVm2H8blKDVGydu1au122bFlYtGhRuPDCCy0Iab4hjj32WAtP22+/fejatWvYbrvtspaddtrJ7t91113DbrvtZqFKg1qUC20Lyf8TlVwhyun+ZKipb4jy51Hw0Wt5EIrpueL3kAxIknzPuUKUxPcTogAAQC6EqBQ1nNQDpcZTtoZatanUEKXPpaIg5Yf16VwmHYrX0M+nw/IUhpYsWWLTy5cvz1k++OADO5RPvZsK6p9++qk9h69v3ZbqOVLaFpLhI1tPlAeeuCQDU31ClJZJPk+2gCS6T+9FsgUf3e//17qtLUR575luCVEAACAXQlSKGk3VPBpfUqWGqJiHFQ8/TUnXldIhfv66pRqcYvUNUdmWiUOM1CdEJZ9H89l6vUT36fn0WnrupOTrJyXDkp5PjyFEAQCAXAhR9ZBs0FW6aghR7qqrrgqDBg0KK1asSNcUjw+rrhClnqgZM2ZY4/7FF18Mr776anjppZfC4sWLbZlSU98QlS14aJn4sdlClJ7Ll8kWhrSevIcoye/LFcyyhSgt63XZ3rPuz/V8AAAAhKg0nf+UrTdKdWqEVZNq6om6+uqrbYQ9jZ5XbB6i/vSnP9k5VD7gxNZbb223rVu3tmsblRqFIP0PxEHFe2u83HXXXTXTcWCKl9PzaJvy+WRRqImXjwOTXtfrc4WeZL0e749JFl82rssWtAAAALIhRKWoseWj8sUNMf0a7vXVpNpC1MCBA5vkkDpfhxqMYq+99gr77LNP+OMf/2hljz32sDB144032jL6G/jfAQAAAKWFEJWiQ6viX6QVqhQgfP70009PL1kdqulwPoUoHc63atWqdE3x+PDqup6U1rGCm6/rsWPHWk/UddddZ/N+PwAAAEoPISpFQWn06NE2rWtCee+TbrOdg1HpqiFEeYDxQ+yKTa+loiCl19S01qmv17vvvjtsuummdlicxMsBAACgtBCiUhSYYprX+RB+naj4HI9q4A33aghRzz33XJg+fXrRe330/F6yBbc777zTLsB7+OGHh1mzZqVrAQAAUIoIUSkKTepx8hLPq2cqGbKakxrg3uD33gxvmPvhYj5IggeffANQNYQod+mll9o5Sr7uikV/I1+vuo2L3HTTTaFdu3Zhyy23rDmkT3/TSl3vAAAA5YwQlaKQVFcpNX6hVvEgpeKNbl3c1WXr+aiNN+yrIURdeeWVYcCAAeHzzz9P1zQPDXPeo0eP0L59+3DHHXdYnf8dAAAAUFoIUSkKSRo8QoftJYvqSy1EaRQ3vafvf//7YeXKlVbnvVGyxRZb1IS/+fPnW10+qilEqSfqxBNPbJIhznPx9a1D+jbffPNw++232zwhCgAAoDQRolLquh5MKV0vZurUqeGHP/yhTeuirRqeW9auXWu35557bthhhx1s+rzzzqu5vyFOOOGEig9R999/v43Q1xQX283Fw5KGN1cAJkQBAACUNkJUSjldVPOss86yw75EPRc6/Es0bLaol2r8+PHWg/bYY49ZnXqpYj6vQwJ1ztfjjz9eUx555BE7F0yDLWiQA/WMSKWFqOQ6aU4elnReFCEKAACg9BGiUnTYW7ZD+RQwfIS+UnHMMcfU9C6pV+qnP/2pTbutttoqfPOb3wynnnqqfa7bbrstfc9XvHH+4IMP1hz2l638+Mc/rglpldoTpcA5cuTIJrlOVF1uvvnmiglRcTD/4IMP0rUAAACVgRCVosCQjUKUeqlmz56drml+OsRORSZMmBB+/vOf27SPLqdG+Pnnn2/Taoy3bdvWpmNqnCsUqSfKe55UnnrqqTBjxgzrhdLQ30ceeWTYbLPNah5Tia666qrQv3//Zh9YQiopRMVhXJ8LAACgkhCiUhQgclmwYEHYdttt03PNT+fN7LLLLjatsLT33nvbtPvDH/4Qhg0bZtM63K9Dhw42HVOA0iAUdTXS43OiKjVEjRgxIpx88snNOrCEI0QBAACUB0JUPaghWCp0aJTejwLUN77xjTB58mSr/853vmPDmqsnSfcrHHzrW98Kd911l92f5CP5ZTtMz+v69etX8QNLXHbZZaF37941A3PoXCk/v6ypEaIAAADKAyEqRQ29XMaMGVPr/c1Bh9v16tXLzucRNfovvPDCmkP6FKS6d+9u713yDUDeeK/kIc59YAkdqvnMM8+URGAhRAEAAJQHQlSKGno69ylb0X2HHnpoesnml7xwbjyvYJBseOt+D1f1VS0hSp9TA0rE60f1zfVZCVEAAADlgRCVEjf4kkVBqpRG6FMDX41+NbDVA6WQ5IefqV7zuk/TWnb16tV5N8Z9+Wq42K4O5xsyZEhYunRpTe8UIarx4v8hQhQAAKg0hKgUNfTKhTf0Y3FjW/fHyyTn66OaQpRG5xs0aJBdf0sX3G3Oz0mIAgAAKA+EqJTaRuerRtUUoi644AK7MPHQoUMtRDUnQhQAAEB5IESl+HWSPEzp8D1dbFeH8vngDNWkmkKUD8rRs2fPsGzZMnqiCoQQBQAAKhkhKkVBacMNN7TgJD6gRMuWLa1ePRXVpFpClJ9b9u6774a5c+faIBM69LG5wgshCgAAoDwQolIUnrzHSb1RHqDUI6WL7SpIVZNqCVGiz6XPq6JBOeLRDpuawkarVq3CHXfcYfN6b+opU2nIuW1N5fHHHw+vv/56em6dXCFKFzXW8m+//Xa6BgAAoPwQolLU0HPeCxUfxkeIqtyeKDnzzDPDwIED7XC+5qSwofDuISrmoy6WmlGjRmUNS14X1ytAbbnllla30UYb2YWjAQAAyhEhKkUhadKkSVbUwFND1ilMVdt5UdUWoi6++OIwePDg8Pnnn9fUNQeFDYWM0aNH2yAXH374oR1qqGHqS1Xfvn1rwtIPf/jDmmDkdSoeok499dT16pO9VwAAAOWCEJWikOQNOwWq2bNnW70as5rXbTWplhDln+nSSy8NJ598crOPznfTTTeFjh07hi5duoQ2bdqEDh06hE033TTceeeddn8p9kTp0Lw4GClUSVynEKXD977zne/U1HXu3NmWAwAAKEeEqDSd+6TzoeIL6yZH7asW1RCi4nOM1BN1wgkn2AV3pbk+6y233BI6deoUdtttt9C1a9ew++672/xDDz2UXqI07b///uuFppdeemm9eYWo5DIzZ85MPxoAAKD8EKKQoVp6ojQanyxZssQOm9N5R/qcTT2Ag7+mXn/t2rU1hxReffXVYbPNNiv5EKVD+OJeJgXAODAddthhGfMAAADljBCFDNUSojwsKQTocDN9bo2E1xyHzWn9enjy17/hhhvs/LzJkyfbfCkbNmzYekEpV1HYYkAJAABQ7ghRyFANIcp7fuT8888P/fr1qzmcr6l7ovy96FZBSkFORowYEVq3bh3uvfdeG/Ri5cqVVl+KNPKeRtzLFpzicsUVV6QfAQAAUL4IUchQLT1R7oILLghDhgypCVHNOUKf+LrW8OEaaOJXv/pV2GmnnSzolbJ4gJZsRSMPKmwBAACUO0JUihp4hx56aHoO1RKi/DNdeOGFNsT5Z599ZvPNcTifU2+Uv756bdq1a2cBSiP2nXTSSVZfypLnQ8Xl/vvvTy8FAABQ3ghRKWrgaXQ+GT58eE2pVtXWE6XR+XSx3eXLl1uIae7P6utfQ67rGlHPPvts2YSo5Mh8XjQ6HwAAQKUgRKWoked0TSjNxyGKIc4rL0R5j4+Kgopu9Rn9fKRc9Lhi0vP7KIG+zjXoha4XNWjQIJuPaXkvpSK+AK+KBpPgwroAAKCSEKJS4hAldc1XumoJUR6Y5s2bF15++WWb9hAjClfiAUXnSjVHWFEAad++fRgwYECYP3++zb/66qvh448/tvtL7W+j0fd++MMf1oSoE088MX0PAABAZSBEpXhjr7ZSTaohRImHpIsuush6T/71r3/Z/OLFi8PChQttWr1AixYtsqAlzbEe3njjDQtRO+ywQ2jbtq1dgPeXv/ylDeQgHvpKic7n0v+NRuxjMAkAAFBpCFEpycCUrVSTaglRHj40sMSZZ54Zjj/+eKvTKHi9evWyIcW1Dk455ZSsh9I1FfU6KThplL5dd9017LbbbmGbbbYJEyZMsPv1t/G/WalQcNJofDfffHO6BgAAoHIQolLqCkmEqMoMUf45r7nmmnDaaadZWbt2bTjvvPPC0KFDLUSdc8454fTTT7eQJfF60OOLHV6yHT6oYLL55pvXXIQ3PgTRqU7vTYcsNldPlQaZAAAAqESEqJS6Bo5gYInKDFH1Ob9JywwbNsyKaN1oXajU5/GF5K/nF+GdMmWKzdel2EEPAACg2hCi0j755BMbka9ly5bW87TttttW7TDn1RCiFEj8M2nae200rRJfcHfs2LHh1ltvTc99RT08Hmyagr/W3//+dztH6q9//asd0nffffeFe++9t6bcc8899p7/+c9/2jldAAAAKCxCVIoClEKTn/8UF9Xr/mpSLT1RHpx064e8rVq1qiZU6VaH9+lCvEOGDAlPPvlkeOSRR8KkSZPCzJkzbfnmCFF/+9vfLESpqEdKZYsttqiZVtF9Ghb90UcftccAAACgcAhRKQoLCky6Ve+TDt/TrddXW49UNYQoD0pOPU8+r8/q4Ur1Z5xxhoWo/v372wVvTz755HDZZZfZsnoef674+YrBQ5R6mbp16xb69OljA2DoVqML9u7dOxx77LH2d/vjH/9og08U8lBUrRd9Rn8fAAAA1YoQlbLhhhvWDBedpHod4ldNPAxUcoiqi3qmvHdKh8fp0Lg77rgj3HbbbXbdI/UGiYcoDxjF5K9VHzrUTz1S6j0Tf2xjin8+3Rb7swIAAJQyQlSKeptqU9f9labaQ5Q+v0JDtlHt1EOl0fHGjRtn876sl2Ly96S/hW49zCSLaNh2hf9nnnnG5rMt15ASPxcAAEC1IkSlKCTNnj07Pbe+BQsWWE9VNfEGcjX3RIlCi9aF38qKFSvCxRdfHO666y6bl6YKFB7UVPxww7jOi2hodp0n9cQTT9i8ZFs2nyIeLJvqMwMAAJQiQlTKoYcear/aa8AAH0RCt5pXve6vJt5ArvYQJckQsXz5cjsvSofLjRw50kbDEw80xRS/D6nt9S644AI7J2rfffe186P22WefRpc99tjDnmvnnXcOy5YtS78SAABA9SFEpagXSr1N6pFKFtXn6qWqVISo3JYsWWLnRA0YMMAuzqvhxkWBJtvhf81FFwfWOVHt2rULHTp0sNvGFo1UucMOO4SOHTuG1atXp18JAACg+hCi0hSU/BpRXvbcc8+qC1BCiMpNQ6BreHMN2NCvXz87tE9Kbf0sXLjQtt3XXnst/Otf/wrz5s0Lc+fObXDR4+fPnx8OOuig0LZtWzusEQAAoFoRohLU8NSw0DoXqloRonLzQ+i0jqZMmRKef/55m08eatfc/G9YaAceeGDo1KkTIQoAAFQ1QhQyEKJy86D02WefWQ/NW2+9ZfPOw1SxQkx9+fvw91soOj9QPVH1oW2m0K8PAABQCghRyECIys3XgwZW0AVudTifBiHR4XM+KInWX3OHqGI54IADQteuXW0I9UsvvTRccsklds0sDbShovVx0UUX2flilboOAAAACFHIQIiq28cffxx69+4dhg0bZqP1aV35taNKoSeqWHSeYJcuXaw3Ki7t27evKRoVUNvNl19+SU8UAACoSISoFJ0Dha8QonLzULB06dIwZMgQGwXvrLPOCgMHDgwTJ060+yo5RF1zzTXh/PPPt94m9UapaDh1FfVK6fpUGgZdQUvXsiJEAQCASkSIStFIfGPGjEnPgRCVnzfffNNG6rv//vttvtqDg86b2nzzzdNz69N25NtXpQZNAABQ+QhRKQpRp59+ehg+fHjNeS3VjBBVf1ov8fWhtO6qMUTFgWi//fazEfx0OF+S6rTsmjVr2KYAAEDZIkSl+OF8GtZcwWHSpEk27xSyqgkhKj8vv/yynR8VnxNVbeIQpZ6o7bffPuyyyy42CIUu0rvddttZXatWrey6VaLD/QAAAMoRISpBPVFqBKrhp5PoVQhRhKjavPjii+Goo46qOScqDhTVIv7MOidq6623Dp07d7ZbhSeFKZU2bdqEl156yZarxvUEAAAqAyEqRYfxyejRo8OGG25ooSlZqgkhKj+vv/66Darw8MMP27zWXzUOqqDPq0MbP/zww/Dee++FxYsX262Gf//oo49sIA71RL366qvpRwAAAJQnQlSKQlLLli1rApN6n+IR+whRhKhcFBwUmFasWLHeuVHVFKD0WbV96La2z3322WeHzTbbjBAFAADKHiEqxcOTglS2UfqqbQh0QlR+XnnllTBgwIAwfvx4m/fBE6qJBymfjovX6wK8m266aXjjjTdsHgAAoFwRolIUoBQYGJlvHUJUfmbPnm1DnPv1k3TtqHfffTd97/o8WCSnK4G2G/9MySKnnnpq2GKLLcLMmTPDqlWrrPfus88+s7J8+fKwbNkyWy5+DAAAQCkiRKX4OVFYhxCVH4Wo448/PgwePNjO+znllFPCokWL7D6FAa1PH+5bh/ypTvOa1nqt5MCgz+aj8Kknaptttgm77rpr+M1vfhN+9atf2fRuu+0Wdt55ZxuQQrS+2N4AAEApI0Sl6HC9ajtkrzaEqPrTelGPinqeNHjCqFGjwqBBg2pClO7X+oxL8typSg9Rvj0pXLZr186CVMeOHUOHDh1Cly5dbCTMHXfcMey99962XLx+AAAAShEhKkWH8+liu1jHG72EqLolA9A//vEP65Hi0NB1tH4UitQb9emnn1rQ1K2Cpx/CN3/+/PVClHrpKjlYAgCA8keISqlr9D2N1lcqFGbUwPRGpgKP13nQ8V/yG9oQJUTVn68XX2fqiTr55JPD9ddfH9asWRPeeustu36ULuD8wAMPWI/V559/Hu64444wduzYiu8B1XrRdljbhXVXrlxp15L605/+ZPP+GNH69XULAABQKghRKQpROi8qV6krZDUlNSj9/Bo1MBWY4kaqByhv3GvZfAOQN1oJUfnTtcZOOumkcOyxx1pPy7PPPhu6detmdbog7/PPP2+9L8ccc4wd3nb11VenH1l9PCgpVOqivN4T5bTtxts7AABAqSBEpSgk1VVKiYLSDTfcEJYsWZKu+SpQqdHpQeq+++6z23x/ySdENdyjjz4a7r777nD77bfbCHTqeVIP1NSpU+1WF55V/Y033miDUKjnqtotXbo07LLLLmGnnXYKf/jDH0LXrl2txANNAAAAlBJCVIpCUrYeKC+lFKIUZr73ve/ZL/d6X3PnzrX6tWvXWnjyAHXWWWfVvO98D+vz5QlR+UmuZzX+k3X+91FwuOyyy2qCbjXybUo9di1atAjt27e326222spG7dPofQAAAKWIEJVSV0gqpXOibr311tC5c2eb1vWI9ttvP5uOG+zqodJn+s///E+bT/6Sr+Xq8+v+wIEDw8Ybb2zTyTCA7LSe4uJ1onXu6/2DDz4I/fv3t3OjnC9XTRQqFaZ0Ad633347LF68OCxYsMB+JNhrr71smfpsqwAAAE2JEJWiwKEep3KgQ8B69+5t0+rF2HLLLW06HtGsTZs2Nkrcj370I5vPRdc3Ovjgg0OPHj3WKzqf5+ijj7br97Rq1cqWpSFbWApRuvjsGWecYWXo0KFW5z1V1UzbsYZB98P5AAAASg0hKqWcrhOlwQk0+ps8+eST4f/8n/9j0x5ydK6UNz6//e1v2+3q1avt1nnYeuihhyxA/vjHP7bApaLpDTfc0KZ//vOfh7Zt29qynNxfWO+8807o16+fBSi/QK8Oa6vG3ijn27AGSdE5UbvvvrvNAwAAlBpCVEpdh/PVdX9TOu2002xkN1FPVOvWrW3afe1rX7OeKvUk6X2fd9556Xu+ooa6j+bnPVhe1BPijVk17DfZZBObrubGfTHoHDZdkFfXk7rkkkvs/LOPP/44fW918m1M2+R2221nh9Hee++9bHsAAKDkEKJSFDbUYMtVSilEadQ3nXgvAwYMsLAkOhRM1yVSz4Z6ODxEXXrppXZ/zANTXfr27VszsASH8xWWzgPyv4H+djoPSMG2mgfw8EMZtR23a9fOrh3VqVMnqwMAACglhKgUhY26SqlQmNEhd/ql/j/+4z/CvHnzrDGu96heDbdixYrwjW98w6bzbZh7YGJ0vuKJe/zUI6UBFfR3rOaw6iFKPVHDhg2zbfw3v/mN1QEAAJQSQlSKAoifF5WtlFKIUkNTh4Ldcsstds0hUeN7xowZ1pPhDXFNz5o1y+7P93wmQlTx6e/oPVF/+9vfbF2/+uqr1gtTrbTd+ToRnRdFiAIAAKWIEJVS18h8pTRynwKRQpTTvIceNUC9ce7LaJ4QVXq0jn2davs655xzbEh5hfZqpe003s523HFHuwgvAABAqSFE5aDhv0tR/Gu9blVU58EnVtt9tfHlCVHF5YevXXXVVeHss88OJ554Ynj22Wetzv92uvV1r+lKF39GBahf//rX4fXXXw+vvfaa3aqox04jTmq9VMM6AQAApYcQlcPo0aNrBpUopcP5mgIhqvjU6+IhSut7ypQptr5ffvllq0uqxvWvc6LUG6VbXWBaA6q0b9/ero3mh7Lm+wMBAABAIRCi6qAwRYgiRBWa9zT5un7sscfscL4rrrjCzm+7/vrrbdubNGmS3a/176GrWuhHjN///vdhjz32CL/97W/DPvvsY4Fq1113tYE4hO0SAAA0B0JUPRCiaKwWmtZxvE4nTJgQBg0aZMPKP/jgg+Gkk06yiyorSEl87lu1yPZ5dbHpbbbZpuaaWhzOBwAAmgMhKkW/eNeGEEWIKjQ1/uMA8NZbb4WHHnooTJ8+3abHjRsXjj/++HDzzTfb/Vr/1RwYfPs7/PDD7bA+hajkOgQAAGgqhKgUhSSNkJatnH766YSoFEJU8WRbt8uXLw8XX3yxhSnR36TaDueL+Tr6y1/+Ejp06FCzLghRAACgORCiUhSS6irVhBDVtLS+fZ27jz76KBx77LHh6quvDkuXLrW6av4b+Po55JBDai7CqzD1/vvvWz0AAEBTIkSlKCQlL7AbF0IUIarYtM7Vq+I9LO+++24YMGBAGDJkSHjggQesrpp7XXyb/OMf/xjatGkTdtppJ7v1ASaEXikAANBUCFEpOmyvNnXdX2kIUc1L6/qDDz6wAKVrRz3yyCM19dXqiy++sNs333zTruHWrVu30LZt2/Dhhx9avQKUBt8gSAEAgKZAiEqpa2CJuu6vNISo5uW9UTNnzgw9e/YMkydPtnn/u1SjZDg6+uijw2abbVZzqKPu1zZKiAIAAE2BEJWiw/XiwSSShcP5CFFNxcOAelVk9erV9vdQqeaAoGCp9eLbYa9evcKmm24ali1bZvPi6wkAAKDYCFEpCkl1lWpCiGpevq4XLVoUbrzxxjB37lybr+aAkPzs3bt3D506dQrjx4+3oeGfe+45eqEAAECTIUSlKCRl64HyQogiRDUVBQFf/3PmzLGLy+qCuzoPCF9RiNpxxx3DlltuaWWvvfZK3wMAAFB8hKgUzolaHyGqefmhfC+++KJdcPeUU04JI0aMsDqsc8YZZ4RDDz009OjRI2y77bbhz3/+c/oeAACA4iNEpS1YsMCGM3eaVi/UpEmT0jXVgxDVvNauXWu32ibVCzV48OBw0003WR3WH2RC50qpJ0qBCgAAoKkQolIUlPzcJ/2q7deG8lJtQYoQ1by0rj0orFy5Mlx55ZXhnnvusXmsC1HeW7d8+XILUYcddpjNVwL9/fU/6P+HAACg9BCiUhSc4tDUsmVLq1NPlE9XE0JU6dD1oi644AIbQAFf8ZC5YsWK0K5dOxvyXNQzpWtKKWSVQ9F71f/WqlWrrAdSn0f1/lkAAEBpIkSlKDjpsCnRreY/+eQTm/deqWpCiCodGqHvpJNOCgMHDrTD+7BOHKI0Sl/Hjh3Db37zm7DTTjuFrl27llXZfvvtbZCMXXfdNbRp0yY89dRT9tnoiQIAoHQRolKSIamu+UpHiCodixcvDscee6ydF/XGG2+ka+HbqC62u8kmm1iIatu2rQWqrbbaqmyK3nf79u1Dly5drMdb0x6iAABA6SJEpSgkJYc09+nTTz+dEJVCiGoeOqRr1KhRoU+fPuFf//qX1dFDsa4nSkWHwy1ZssTClN+qF7mcii4YrEP5dNimLiD8xBNP2GfU39l73ArJn9PXIQAAyB8hKkUhqa5STQhRpeWjjz4Ks2bNCp9++mnN34HGb+W59NJLw2abbRZmzJhh8x6iCl0UzFV8GgAA5I8QlaKQpHOfchVCFCGqOenwrquvvjp8/PHHNq/GL71Rledvf/tb2HjjjcMzzzyTrikuH0ofAADkjxCVosP2alPX/ZWGEFVa7rrrLhtY4vrrr7fR+uJeBVQOhSiNNHjrrbeGefPmhZdffjnMnj27oGXOnDnh+eeft15Nth8AABqOEFUHnbOw5557pueqAyGqtPzzn/8Mp556aujfv3949tlnrY7eqMpz3nnnhc6dO9sgEy1atAitW7cuSNliiy1s0I3NN9/cRv/baKONwnXXXZd+VQAA0BCEqFroIrt+DalqQogqLeqRuOiii6w36oUXXrA6ncvC36Qy+HWhdMimhmnfb7/9Clr+8Ic/hD/96U/hz3/+c/jd735nIwLefffd9poAAKBhCFEJuhaPRuTbcMMNawaVIEQRopqL/y1ee+016z149913OQyrwvj/VlP8j9122212AXEdIgoAABqOEJWiQ/bGjBljh+3FwUmNDR/yvJoQokqL/h46h0XnQ61Zs8b+FvREVQ79ff0cNx8tz+cLUcT/p++88047rI8QBQBA4xCiUpK9TgoPcXDSCH3VhBBVOvxQr/vuuy/07NnTBgWQuIGM8hYHnmL8TfWcvh2pJ6pVq1Zh3LhxNu/8fgAAUD+EqBT1Quncp0MPPdR6paTaep9ihKjiUU9SPrxRrXNYdMFdH1iC6/ugvuJgpp4oDS5x0EEHhR49eoSDDz7YRgIEAAD5IURFNASwDt8bPXr0eiGKIc4JUYVw//33h/333z89Vz/+t3jsscds9DadGyVffPGF3QJ1UYjy/99rr702bLLJJmGrrbayH440at/bb79t9xHMAQCoP0JUFn6OlMKTbqutV4oQVXjqgdpyyy1tW3r88cfTtXVTw1aN4JUrV1rxw67i3gWgNtpWPCCp12nixIlh+vTp4fDDD7eR+hisBACA/BGi6sDAEoSoQrjiiitsO1LRtYDyNWHChNC3b9/wyiuv2LzC1KpVq9brZQCy0TbiJdarVy/riZo/f77Ne2DPt2j702N1q3kAAKoBIaoeGFiCENUYGlXvO9/5Tk2IUlGoqg//W2hgiSFDhoSzzz7bhuAfNmxYOO2002zUPvHlgLr4tqJzonRYn58HCgAA6o8QlaJGhAKDhjjXBXY178Od67yBamtkEKIK67DDDlsvQKlstNFGFq7q4odh3XvvvaFfv37hxBNPDIMHD7YAddJJJ4Vly5bZ/UB9xSFqm222CUcffXQYMGBAOP744+1/viFFvaRHHXWUnVcKAEA1IESlqBEQN3D1S388r/urCSGqcGbOnLnethQXBaL6UpBftGiRBS8dxnf++eeH3r17hw8//NDuX7t2rd0CdfH/b4V7jdSn86J0q0P72rVrl3fZYostwnbbbWfTTz31lD03AACVjhCVoutEqcdJ5z/pVg1cDSghClS6v5oQogpH5z8lw1NcXnrppfSS9ePnnOjcKAU0n/fzU+JR+3TelNcDzv+/p06dGv75z3/asOeNKeolPeaYY+zQwHwGTQEAoJwRolLUmF2wYIFN61bzTj0A8Xw1IEQVxqhRo2rCUq7y61//Or103RSG/G9z+eWXh4EDB9YMCuA9UUuXLg2ff/653TpCFGJ+iGghXXzxxXYR32o7fxQAUL0IUSlqzMbieUIUIaohdNidznvysFRb0fWj6ssDkQamOPXUU+08liVLllidaOCJ/v37299u+fLl9ncrRqMZ5Uvb0OrVq2278P911TWkOIUoHRL49NNPp2sAAKhshKiUbA3bZKkmhKjG0/lO8fYTH9bXtWvX9QKWpnUdqbqo0ep/h6uvvtoGmFBvlEbo83odkqpBJ04++WQCFDLof1vbhYq2Jw9SjSmiC0G3bt06PPPMMzYPAEClI0SlqCGr0fhyFd1fTbxhRIhqGJ3n5AFJZa+99rIhyX1eh/D5RZy96P66xCFKh+/5daL87yU6J+qyyy6zkfsUzLyhDBSTQpR+KPjzn/8cunfvHrp165az6PwpDWqhi/0edNBB1pOq7RQAgHJCiEpRI7Y2dd1faQhRjaOQFAckhapkiJK4d0rXkapryPNkYPJQpRIHJQ064YdVMWofmoKuYaaBJVTat28fOnTokLWot0qjAXbq1Clsv/32tqwOOwUAoNwQopCBENVwr7/+ek0wUvFhzLOFqGSP1UUXXWT1ucShKRmmNO+/5ut59Ld7+eWX1ztfCiiWOXPm2DX2Hn300TB58uScZcqUKVY0AMW+++5rwYptFABQjghRaRpAQueTtGzZ0hq0PuR5NSJENZxClHqVtA3FF9TNFqJEFzr1+roO6VNI8qCkv5EHp3hadDifzpcaNGhQuOmmm6wOKJaG7huOPPJIC1GfffZZugb58P935/sCAEDTIESlKED59aGSRfW6v5r4FzEhqmE02p4C0dtvv52uyR2iRCPtqfeoPoNL1EaH9KkhNXLkSLsY7ymnnBLuueee9L1AafBDT//0pz/ZIa0rVqyweTRe/GMKAKC4CFEpCgtq3OpWvU861ES3Xl9tPVKEqMKrLUQViv+N1IiaN2+eHUp4xx13WB1QCrRv0UWgRYNQaKTKAw44IBx44IF2S6l/UQjVwBxad3/4wx/CVVddZeuVgWQAoGkQolI23HBDGy0tG9XrEL9qQogqvGKHKD+URw1U/a3812gaVCgl3lsqavhvueWWVjQgRbt27Sj1LG3btrX1plsN0qHBOjRCotATBQBNgxCVooZtbeq6vynFX5BxQ1nTPh8HHt3noai+CFGFV+wQpb9Z/Hf++OOP7QcADS6RTX22CRpjKDRtdxqGX2bNmhVmzpwZXnzxRbu+lOYpdZfnn38+vPDCC3b76quvhhtuuMHC1OWXX27rFQDQNAhRKWrYzp49Oz23vgULFlhPValQw1aNEN0q2Hi4UVjStIa01n1xIznfAOSPJUQVTlMczhfTdtu7d+9w6aWXhjfeeCN8/vnn4eGHH7YR0vyCqJpW3fTp023+iSeesPs0Tw8WUB6ee+65sOmmm4YLL7zQ5uvzAwkAoPEIUSmHHnqoHbKnIXp9EAndal71ur9UJMOM5r0nSgMTJO9fvXp13j0KhKjCa+oQ9dZbb4X+/fvbRXfvvfdeGyVQIwEOGDAgXHDBBbbMUUcdFU4++WSrk9NOO82W18h+XF8KKG3+Q4euCUeIAoCmR4hKUS+Uepu8kRsX1efqpWouGsL6a1/7Wujbt6/NJ0NSt27dwje/+U27lXwDECGq8Jo6RC1atChcffXV4corrwyPPfaY/Shw7bXXhlGjRoWxY8faMtddd10YMWKEHfanbejWW28NQ4cOtQunCn9zoHQlQ5RfZy7fH80AAA1DiEpTUPJrRHnZc889Sy5A6Vh4vbeFCxeGX/7yl3a4lvgX6vHHHx9+9rOfhWXLltkXq3oakhSSVOo6ZEvPpdcQft1snKYOUQ2lUHXxxRfnFaBotAFNz/fJOvx28803b7ZRZPn/B1CtCFEJCk0a4lznlDjNlwqFpn322cem1dPgDXJv9N59993hzTfftGn1Qmy//fY2HdOXXn0aybrOkIKYEKIap1xClHqsFMD19042jny70a2Kh3C2DaBp6f/PB+jQ91ObNm3CjjvuaN8Nu+yyS/jNb35T0PK73/0u7LbbbuG3v/1t2H333e21+vTpY6/P/z+AakWIqoMalWr4lgr1Dg0aNMimH3300fCjH/3IptW49euvuK9//eth/Pjx6bmv+JfeQw89ZJ/tG9/4hh3+p9vvfe97NUWH8mkYXeGLsnHKJUQpOA8cODAsXbrU5pcsWWKhSqP9yfLly22QCtUrRKkxx7YBNC3/IUP0PfCLX/zCLgyv4c81XHwhS4cOHWwYdQU1TatO1/fSdb4AoJoRolLU66RD95LXi1KvlL6YSilEHXvssXaukjzwwANho402sml9oSpE+RfrFltsYRdjlGSvky+j4a8PPvhgG2DAS/fu3e1W51PtvPPO9jxCQ7lxyiVE6Xyos88+u+Yw0DPPPDP069cvnHDCCTZIiQ4Z0jKaV7iSZHgHUFzaH/v/nX7Y0HDnL730ku3T//Wvf9nQ54Usek4VHeWgYdYVpA477DB7fQCoVoSoFI2+5w1cFYUqhSkfbEJBqlRccsklNV9et9xyS9huu+1sWjzo7LDDDnYVe5ft3Ke6zocSjdS28cYb2zQhqnHKJUSdc845NkqfwpP+5rqA51lnnWW9Uwrj2v70WU4//fTw2WefsV0AzSTujWpKOoywRYsW4S9/+YvNax9QiOKfpzk+EwA0BCEqRQ1b9e7o2HL90u69TyrNdbJuLnPmzLGR+XSYoQ7dGDlypNXrmkCiXgS97wcffNAuwqhDPfKlLzRhdL7CKZcQpaHNVVatWmXzGjZfJR7yXEMpq6dKIYpGD1Ad/Dtg5cqVdpi3j/4qcQBqaIkDFQCUA0JUihq2CiXi50CpF8oHlCilgSVEvQQ/+MEPwiGHHGLz+mVQozOpoavD8XQYXvv27UOrVq1qrgGUD0JU4ZVLiIr54ULaHvT398bOvHnz7NAev091ACqbfwfonEh9txT6+om+LyFEASgXhKgUNWxj2UJVqUg2WOsTbvINQISowrv55pstPKmceOKJ6drS440YBSj9zX06du6559oAFApTuo8L8wKVz78D1BOloyB0WPl7771n+4H58+fbbb5Fj5s7d649jxCiAJQTQlSK9xDUVkpJHKT8S8e/eLzhK8nb+vLlCVGojc6Ze+6559JzACqVvhP8e0GH8WqkPh32rktodO7cOXTp0iXvsvXWW9tofx07drRRZyV+HQAodYSoFIUkfSFohL5kKbXR+ZoCIQr1oUNFdY4egMoWhxudL7nNNtuEPfbYw64fpetG5Vv0OF1zau+997bn0mifou+Z5NEWAFCqCFEpdYUkQhQhCpn69u1rQysDqGxxsNHhuzoPV4fyqmik14YUPecbb7xh51f5JRX03UOIAlAuCFHIQIhCfeh8QTWmaPQAlc8DTiH/3xWidC1CP09U3zP+/QMApY4QlaKL6rZs2bLmsD4fVKJaEaJQHzqP4cUXX0zP1c23Kz9kx3+NVr1PAyhNcYDy6YYWp8El9N2r69BJvI/QdLwsAJQaQlRK8mK7Cg/VjBCF+tCvxxq6/bXXXgvvvPNOGDJkSLjgggtsCP4ZM2aEFStW2IV6zzjjjHDqqaeGyZMn2+N0oV7NX3XVVTafbFgBqA4anU8X7tVon0n6YUXU2w0ApYgQlaLg5BfV1a2uEVXNCFGoD50TddRRR4WXXnopvP/++6FXr141dU8//bQNhXz00Udbj1XPnj3DuHHjrGGkC0MrRClwieq8wQSgerz11lt2TpSueXjTTTeFUaNGhUsvvdQO8/MfVtg3AChVhKgUhahYXfOVjhCF+li0aFH46KOPwurVq21+2bJldqK5hkBWw0eNIF2YU6N5qU7Tsnjx4tC/f3+73pRoWbYvoPosWLAgbLrppnYYvS4Qr6HP1TOlH1xEg1iwbwBQqghRKQpJ8bDm2earCSEKxaJtS9uSzoV4++23rU5hS0FqzZo1Nq3QxeF9QOXTfkA91aeddloYOnRoOOKII8KWW24ZpkyZYvezHwBQyghRKQpJdZVqUkohygf8SBaF26agX0r1eoVQyOcqZzrH4brrrgv33ntvuuYr2vZ8+wNQubIdpnf11Vdbz5SfP8m+AEApo0WXUlfDttoavqUUokTvw89ZEw8jCljFptch+BSOH+KnX501wMTdd98d7rjjjnDLLbeEJ5980pbR9kfPJ1DZvJdJh+y5v//97zbkOSEKQDmgdZgybdq09FR2dd1faUo9RIkHqWR9odF7VFjattQT1a9fP7vA5kknnWS3AwYMCHfddZctU9e1p3RftpJLtmVVkvcBaDr6n9P3ShyULrvssrDJJpuERx55JF3zFQIVgFJD6xAZyiFEier9sD4PO1407+JDAr1ewThe3uk5VVSn5/bnHTNmTM2ydT1HtkMQRcvHvWeqj993HNb9PSTry50aTvrl+cEHH7Rfm6dOnRruvPPO0KdPn3D77bfXLJMs2iZV4ulkyfZYybasit/ng2AAaB7+/zdixAgbrU8DS2iQGvVaL1++3Eb61P+q6gCgVBCikMEbmGrIl3qI8lASLxNPKwgpAInqVSSu92k9RqElDjoecvxxuvXglu05xF/bH6sQ5NP+3HHQkvg969Zfz4NapVAjKHkuhEb4U4CaNWuWzfuv03EYiudrEz+mrmUBlAb/ftHw5p07dw4777xz2GmnnULXrl1Dx44dbfAJ4X8aQCkhRCFDOYUoDzTOw4kvX1cA8SATB634tTz8uOS8JJ/DJety9USJXldF9Jn8Ob34cuUuDji+nS1dutQu2Pvpp5/afH00pjFFQwwoLf79cvHFF4etttoq7LLLLjbc+a9//euw/fbb2yURhP9dAKWEEIUM5RCiPMx4vW49bMTL5wogWkb3SdyLlHwtfx2neQ9CuZ5DNK/7Y/mEqGQgqxRqBOlwPm1jOvdJXnjhhdCjR48wevTomp6qV1991YZAV/FrTOnCnCrz58+3xyp86X6vF/Vq+ePee+89q/vggw/CO++8E959993w8ccf23tYuHChXefKl6FxBjS/Tz75xP6vlyxZYofxzZgxI7Ru3ToMHDjQ7te+Q/+rzVn8+1HTAKobIQoZSj1EebCJA4mm/dyhePlkmMkWrvIJUfH9tT2H5p0vX98QpeXj19S8L1dJfDubM2dOOPHEE62MHz/egpQGnlDD6dhjjw1vvPGGXU+md+/eNhCF1pOC1cSJE21aI/3pPrnpppvssSoXXnih1Q0bNsx+yVbdyJEjrU7PM2jQoHD22WfbPIDSo/97XTfK9436gUXfRc1VtG/Srd5H8rBkANWHEIUMpRSiFDoUKJIlDjriwUPFH+OhxuvjOn02r/Pl47q4J0jTXu9f5pLtOc4555yauvg+D2MqCljx54rfu3+u+Lnj16xEr7/+ejj//PNtyPNHH33Uep00rTpdhFPrTj1GZ511VrjooovC4MGD7dC/xx9/3ALSueeea7eia0+dd9559lhdi0rUw6X79bfRCevy17/+1UYF1PMBKC3+HaQfUNq3b1/zI4m+h3RfcxX1PvmQ7JoHUN0IUcjgXw5qvJdCTxQqk7YpPzxGwckbKuK3arDoF1/N+8hcvly8TWZr2Ghaj/XDcETPoWkdKqTwpRI/BkDz8/9Jhag2bdqEU045xeZLhe9PAFQ3QhQy+BcYIQrFpu3Kty1vmOhW26CHJvFDZ1SnaX+Mz3s4Soqf2++Pt2UPWXGQ8un4vanOH++v5fPi817n0/Hj/TZeTnxay2ral/HPDFQb/79RiNp2221toIk99tjDevF125xlt912s8EudI4lgOpGiEIGb/ARolCpFFJWr14dVqxYka5Z15vlJ657kMm23fv94gFOt14nelz82PgCwlpOj9GtlvHH+f16LtUTolCtfNt//vnnw8Ybb2yDS+j6UaVQtttuu7D11luHZcuW2XsEUL0IUcjgjTpCFCrVmjVrbPvWuVEKL344oKgBp9Dj/wd+K3GdllMYcnoeH3FQfFmFNac6/1/S8ip6DhXVq6jOG5GaBqqN/2/oMF/1RmlEzlIoCk5HHHGEndOqEQQBVDdCFDJ4448QhUqlYHPmmWfauRY+ip8GENE2r0EtBgwYEF555RXrqerVq5cNQnHCCSfYdWxk1KhRVjdkyBC7EKiGadd5VprWY/v06RMuv/xyW1YDXGiUQT1e98+ePdsGxujbt6+NLKiBMjQYhowYMcJGDuzZs2fN8OtAtcl2jmOpOPzww+1aVhqOHUB1I0QhAyEKlU6/cGvIcwUhH9nv9ttvt2HVFWoUnP71r3/ZUOpaTmFLQ7Bfcskltuy1115r/x8KTApDL7/8cli1alU45phjLBjpeX3Zq6++2h6rcHb00UfXXFhYw66r6DU9yClw6bEafp1GGqqZvnPinttSsf/++4cOHTqE999/3+bVY1aKYQ9A8RGikIEQhWqggKQLe+rQPlGw0cV4dciOAoy2eR1Wp3n1Mvmt+LyC04cfflhz+JHq1HulWxXR/fHj/VA9XRh45cqVNY8RHQ541VVXWY8VhwsBpeewww6zc6P0f+sBihAFVCdCFDIQolDptI1rm/bw49u3z6t42Eny856SjScPY07PqRKfNyXJQSb8OfwQJgUtBazk8wFofgcddFDo1KlTzQ8qAKoXIQoZvFFHiEIlU0jysOShxgNUHKo86HjRfb6cih7vy8fL6Da+3+vFB67w4KTl3GOPPRbuueceQhRQgg499FAbdv2QQw6xXqn99tsvTJkyJX0vgGpCiEIGNe6EEIVK5QHIpz3w+LTP+/9CzO9P3ufz8XOIbj1E+byWEV/W50XnR2lwiTvvvNMCmA4tfOKJJ6w88sgj4aWXXrLldDtt2rTw5JNPWvDSoYgKZZp+6qmn7D7dysKFC8PkyZPD448/bs+j87Jk+vTpNq/l9Nw6rFCDbjz88MNhxowZdr+eR2bNmmXL6jlU3n77bavXY1W0rF5bNCjGhAkTwkMPPRTefPNNqwMqwb777hs6duwY2rVrZ0Odb7nlluHBBx9M3wugmhCikMEbe4QooOmNHDnSBrfQCH86T0vXyunevbsFKw1ioWHZ5ZprrrFR/HT+lAa0UDDSOVY9evSwwTD0/6v7RaFHy/jIf/fee6/Va8AMjRyo59CgF3PnzrXQphHI9BwaYEOjGIpGJNSyqteyCkmiQTP0vlSv9ykzZ86096FBMyZOnGh17ENQCfSDgX4s0I8MZ5xxhl3DaurUqel7AVQTQhQyEKKA5qNDg2655RbriVKv0KJFi2z49VtvvTXcdddd1ksk6jnS/Pjx48Ntt91mvT8aKEMBSeX++++3x8m8efNsWvV6HjUA5YEHHlhv2cWLF1tw++c//xnGjRsX7rvvPrtP1CN19913h7Fjx9p7U0+YetB06KHq4td75513wvDhw230wUmTJlkd+xCUO/9udH//+9/DL3/5S+vlBVB9CFHIQIgCmkeykZacFwUX/T/GhwC6bHW5FOt/2t+DgpR6y3QYoOryeW9AKfLzJ/3/Utd10+F8hCigOhGikIEQBTQPDxpx4PAAkizOp5P3xcu4uu6XbMvEdS5bnWj/oXpdi0tBSr1jkhylECg3ye1d14Br0aJFzbmHjaHnVkgDUD4IUchAiALQUL6v0LlcRxxxhA0uIexDUGl0OJ8GmNBgMDpsVYfW1rfocFnd6txCHR77+uuvp58VQLkgRCEDIQpAQ/n+44UXXrDBJfyke68HKsUll1wSOnfuHLbffnsbsS/f0qFDh7DVVlvZ4BT/+Mc/0s8KoFwQopCBEAWgofy8ER3Gp/OhPvzww5p6oJKoB0nXijryyCPtBwONWplP0UiZBxxwgIUoDeICoLwQopCBEAWgoTwsLViwwA5x0q3oAsOxbKEq236G8IVKpiDWsmXLcMcdd6RrAJQLQhQyEKIANJTvPzQkeu/evcPo0aOtN0q9U3PmzAmvvPJKeOaZZ+zCwOqt0mF/qveLCOvcENXpIsK67hWHAaKS6ZIDhCigPBGikIEQBaChfP/x3HPPhUGDBtVcK2r58uV2EV9dnFeHMumaVApKmlad9jcKWrqor6Z14V6N7gdUMp0LRYgCyhMhChkIUQAayoeBVojSdaIuvvhi62XSkOcaEloXBr7iiivC+++/H1577TXrqbruuuvCDTfcYI9T4DrrrLMsfL377rtWB1QqD1GcEwWUH0IUMhCiADSnhx9+OPz1r38lRKHi6XC+bbfdNvz5z3+271z/McF/jABQughRyECIAtDUtN9RwzHZePT9EVCJrr/+euuJUpBq06aN/XggyYFYAJQeQhQyEKIANDXtdzxIffnllzbtw6UDlUqDqowZMyZcfvnldt2o888/3+rZ7oHSR4hCBkIUgKbmAcr3P+Lzus3VqPT7st1f2+OktvuSsj1XrudP1mdbzuf9vniZ5HQsvk+S87Fc9fVV2+P9db24bHWSra7axdv6jBkzrEfqnHPOsXm+c9Gc+F+tH0IUMhCiADS1ZINS54p89tlnNSEqSb1VSdn2UxpKPZts159as2ZNeuorep3k6+t1sh1ule09ZXv/ms/2vrK9vpbL9vh4fblsr6/3mVwv2T6T5Pr82WRbf9mWTb623rfqsv2tqpmHKD+cL9vfF2gq2v607+A6fbUjRCGD77wJUQCaStxovOWWW2z/889//jOsXr06LFmyJDz++ON27aknnngivPHGGxYCNK8yffp0u/aU6PAor9eyGlpd16mKHz9//nwLJ0899ZQVDbU+c+ZMe/yLL75oy2jZxx57zBoSn3zySXj00UdtfvLkyTayoF7fl9Pts88+a4+fNWuWPZ/q9Jp6/x999FF45JFHrKH80EMPhffee88Ch55Pdbp9+eWX7fG6RpaeU59J9VpOw8HrcVpWz/PBBx9Y4NFrqOj1nn/+eXu8RkWMP6vWq5bX+9Zjp06dau9f70vL6fNrOX1u0XrU8/l9Wk8aal7L6DlVr8frGl7x6/t1vrQe9N61rB6v19ffS6MuLlq0yOb1fZItxFWzp59+2kLUBRdckK4BSgP/q7kRopCBEAWgqSVD1EknnRT69OljDXYFDF1P6vjjjw+9evUK9957ry03YMAAq9NFfc844wyru/LKK21+4MCB9hgFKAUTPU7Dph977LE2nLQaBn379rXX0b7uzDPPtMfr3BS9ri+rsKELBHfr1s2es0ePHhYSFK50v5bT82god7nsssvs9VWn97Zq1aowe/Zsu0bWKaecEo455hgLbApHel0to+e58MIL7fG61eurXs+hEKOApMfp8UcccYR9HoWofv362bJ6/CWXXGKP/9vf/mZ1Wjd6H3r/CkZ63yeffLK9DwXNjz/+2NaJv74+t2h4eb2urt2l59G+f/z48TWfVY9RUFKw1HOqrmfPnva5RetRr6vn1fuTsWPHhoMOOshClXCuWyaFqNatW4fzzjsvfPrppxacKZTmKPrRRT94qGhbRG6EqDKlBod/EXnjw7+UNB9/QeX7ZUWIAtDU4v2UejZ0OJ+uobNs2TL7Ur/rrrvCAw88EO6++24LAVpejXM18CdMmGDTop4RTSsoqejx6vm55557wrhx46zOe2203P3332/1em5Rj5OW0fPqNRV23nrrLXu8lr399tvDwoULbf+rOi2nevXQiG71flT0XvV4DdWuZfW8un377bft8XqcHq9QqB4iUe+TXleP1/25Hq99sp7fX0uPE31+f15/fX1+XZ9Lj1edHq+eJE1rHej1/fETJ0609aHi61S9a3qs6vT6ej96vD9W92m9iZbR+/HPpfepEKlR6ObNm2fL6G8Xh+ZqpXXg360KultuuWXYddddbaS+7bbbjkJptrLTTjvZ9njttdfa9onsCFFlRjtcfSlq5xt/CelXUf1i6cHKGyTxTrq+/HkJUQCaWxyu6pLPstk09+PjfXpDlMPnb+xrVJL4e1yHWm6xxRaha9euYYcddqBQmrVsv/321jN644032vaJ7AhRZSZbmFFwUr1K8gtKvxbm+8VMiAJQSrRP0r4tW/GGaG3LqMTL1bZsfZdTachyyWWT98WltuXi+5KlIcvls2y2+73EyyXFj8U6+v7Wj6CiQzTj9UehNEcR9SjrHD1CVO0IUWXoqquuCt/+9rftmPOYeqjktNNOs/uHDRtm8/nyfyJCFIDmkGyM11Zi2e73kpRtGZWkbMt4iWW730tSbffFalsuvi9ZYtnu95KUbRkvsWz3e8kmDk5axo+YwLr1Ea8foBTocNxWrVqFUaNGpWuQDSGqzGgEpA022MBGl9pkk03CiBEjrN5Djo5X/+Y3v2nHwGs5P84+5jtrf4zvwFXiL0GdXOwhKteXIwAUW7yPSpZYtvu9JGVbRiUp2zJeYtnu95JU232x2paL70uWWLb7vSRlW8ZLLNv9XpJUp++P+PvGgwPW4UdKlBr1RClEjRw5Ml2DbAhRZUYjMO299942rQD129/+1qa9F+rggw8OQ4YMsekTTjjBRpRK0heYfgmsi0a7UlATvvAAAAAqnwa32Xjjje3IJ+RGiCozOsROw9yKRkP6yU9+YtMeitq3b18zmsrw4cPDjjvuaNPZ6Loj6q361re+VVN0GKCXn/3sZ6Fdu3a2rIc0AAAAVK6HH344dOrUya7Vh9wIUWXGr+shGpJXQUf8cDuNqHLdddfZtK43olFWkrxXScME77vvvnbdkLh07949HHXUURbA1J0r9EQBAABUtvocqYR1CFFl5qKLLgpHHnmkTesXgi5duti022+//cK5555r04MGDapZNkmjANVFF6HknCgAAIDq4D+a61bn6/Ejem6EqDKjK9XrEDxdQFJj+Pvxqrq6vILOnXfeaYf4rVixInz/+98PDz74oN2fDw9MjM4HAAAAZCJElaGzzjor/Md//Ec44IADbF4X2d1oo43Cp59+avPqfVLQUgiSfAMQIQoAAADIjRBVZpLHqia7WRWoYro/3+NbCVEAAABAboSoMuQhR7cKSSqa9nkPTX5fvghRAAAAQG6EKGQgRAEAAAC5EaKQgRAFAAAA5EaIQgZCFAAAAJAbIQoZCFEAAABAboQoZCBEAQAAALkRopCBEAUAAADkRohCBg9Rxx9/fNh4441tGgAAAMA6hChk8F6nY445JrRs2TLMmjUrPP7442H69Olh2rRpdZannnoqPPnkkzbtj3nmmWfC008/HWbMmLHespSGF1+XWrda55rXen/00UczlqUUpmh7VtG2rHWebRlK44uvZ23TrOfiFW3H2rdrvzFz5sysy1AaV7QdP/bYYzbt27Jv3/pujZelNLxofWob1j5D01rXTzzxhN16e4RS+KJ1rvWt6brWcyUiRGE9X375Zc0Fevv06RM22GCDRpWvf/3rWespFAqFUhrlG9/4RtZ6CoVCKVSpRIQoZPCeqLlz54bJkyfbLzlTp061XxnqW/TrxIgRI8J3v/vdMG7cOOst0S8R+kUu2/KU/It+/dEvbVrXHTt2DPvvv394/vnnbV1nW57SuKL1PHLkSNumx44da/PZlqM0vmg71ja9zz77hDlz5mRdhtL4ol/tR40aZSFq0qRJtk/Jthyl8UW9Tl26dAl//OMfbTruBaQ0vqidoqJt+sorrwz/+Z//Ge69996a3uxsj6E0rmjfvMUWW4QDDzwwzJ4929oj2ZbzUokIUViPeqEUorw3qjG089KvD0uXLk3XoFhat25t57ChuF588UXbppcvX56uQbFstdVWoWfPnuk5FIsaPtqmV65cma5Bofn3adu2bcNhhx1m0ygetummoxBVzftpQhQKzr8w9MuDdmQffPCBzaOw4qDbvn37mh0ZIykWj36p1zb9/vvvp2tQLOqJOuKII9JzKBb1hmibXrZsWboGxdK5c+dw6KGHpudQLL5Nf/rppzbPd2LxKET16NEjPVd9CFEoOEJU0/BRFIUQ1TQIUU2HENU0dIg1IappdOrUiRDVBAhRTadVq1aEKKCQCFFNIw5R7dq1I0Q1AUJU0yFENQ1CVNMhRDUNQlTTIUQBBeY7LD8uefHixTYfN/rRePHhfB06dKgJUazn4tHJ4ISopqFDnwhRxcfhfMXn+2Rt035OlPbf8T4chePb9Mcff2zzfCcWz5ZbbmmXw5Fq3J4JUSg4/0fyHZn3RH3xxRd2i8JQWPXAGh/O9+9//5sv5yLRKE/aphctWpSuQbHoJHx+tS++KVOm2Dbtv9qj8LwRr226e/fuNq19N437wtF3nr77RNdKjEMUbY/iadGiRejWrZtNV+P2TIhCwXkD3nuiFi5caPOqp3FfOHFY0kWR/Vd7vpyLR8P0E6Kahr6c6YkqPg1trm36o48+Steg0Lxxr0OfDjjgAJtmP11Y8Y+Kvk0Toorvf/7nf8Jf/vIXm/b1X00IUSg4/2LQNQQOP/zw9brUq/GfrFi0Pn1dn3XWWeGaa66xadURVovj9ddft4b9kiVL0jUoltNOO61mm0bxaD+tHr/PPvssXYNC00XsRdv0VVddZdPaR/N9WDhan76edc0ibdOffPKJzfv3JApv8ODB4frrr7fpalzPhCgUnH85JL8g+MIoLK1nlfhXNu3E/FdPFBfruWmwnotH+w8Ul9Zxth+22K4Ly9ezBymnebbz4kuu92pBiAIAAACAPBCiAAAAACAPhCgAAAAAyAMhCgXhxyP7tB/vrWmdsxPfj8Lw4+y9iN+icLSefV3H2J4LT/sK7Tvidcs2XTjZ1qWfqxqfs8r5q42nda31qNu1a9fW1Ely/fqyaBydl+P7Du1Hsq1T9tuNp+01Xo++nYvX+3ylI0ShIDw0xQ2gl19+2W5FdXxJFJbvpD7//PPw3nvv2bQaoVrX1bIDawrabn2b1kiT7777rk17HQpD6zkeJGXevHnpKRSKtlkVX8/vvPOO3fq++Y033girVq2yaTTc6tWr7VaNev9ufOutt+xWdVrHGjlOFzjW/tuxT2kcH9xA34e+LtesWVOz7rXeVc/3Y8P5etXtq6++atNx204Xos8VYCsRIQoFEX9Z6KKNukaDiq6LIXG4QuHceuutNes6vk4UCse/cK+99tqadX3wwQdbHQonbvT86Ec/svX8jW98o+ZXfBSG76fnzp1r69hD02677Ra+/vWvW90VV1xhdWg47Yd9X3zJJZeEH/zgBzat78qvfe1rNfsSv1Cp/13QOLpm0c4772zT99xzT81+pE2bNlbH92PjPffcc7Zev/nNb4Zvf/vb9mOA6AdG1S9evNjmqwEhCgWhhqb/unnUUUeFo48+2qZ/+tOfhvHjx9s0IarwNt10U7t2kWjntXTpUptG4agRr21b69cbOjvssENYsWKFTaMwfP9w7rnnhl133dWm+/btGw488ECbRuN5A/K+++6racjL1KlTraEp+hXf69Ew+j70XpHjjjvO1me7du1s/oMPPggbbrihTTstr8J3ZMNp2953331tXR9yyCFWp+9HXXhXFGKffPJJm0bjbLzxxmHEiBE2vffee4czzzzT1q3WvYofGVMN2FOiIPSF4b/Yt2jRItx999023bNnzzBo0CCbjg/VQePFX7g33HBD+K//+i+bjv8WKIxnn33Wtmv1/PXq1YvekSLwBr6+lC+44AKbfuKJJ+yHGOEX5MbzdXjSSSfZ4dYeltT75z8K6BAd/cKMhtN3nfbD2k8cc8wx4amnngq/+MUv7D4FVv16r56/3r17W53+LiqEqIZbtGiRXcz4uuuuC7/73e+srn///vaj7iuvvGIh6sMPP2Q/UgA6ZM+31d/85jfW03rRRRfZRY71AwE9UUCe4p2//ommTJli0/qyPvzww21av+LTuC8c7xVRQ/P73/9++P3vf2/z+lvwRVFYEyZMsAbngAED7Jfl5C/JaJz4V/hx48bZ9rxgwYLQtWvXmhCl+9l/NI4a9vG+2kNUTOtbvYFoHO2DfXt95plnwk9+8hObvuWWW0KnTp3CjBkz7IcZD1Js34UxatSomhA1ffp028Z1ePA222xjdazjxvEeVrn//vtt/cbn9emQYPW2VgtCFArGd076Ep44caJN65egHj162LQa/fEXOBon+WWgLnZ9gaDw9Ety3ODU9IsvvpieQyHo13sP/0OHDg2tW7e2X5b9F3ztO9h/NI72Gb6OtT9OhqiNNtooHHDAAek5NJQHIt9ep02bVvNjQEzh6nvf+55Ns20Xhr4D/QdFbd8zZ8606Z122imcd955No3G0yHBWr9z5syxeW+P6LBgQhTQCL/+9a9rdlZbb711uOqqq2yanqjC69ixY82J4W3btq1Z13whF9b8+fMzQpSPbIbG037BD5HUScsPP/ywTV922WVhr732smk1/r33FQ2nde374nib1sn4PsgBGkfrVsUDq0LUf//3f9v0xRdfHK655hqbHjt2bM2PBFqe/XbDaf3JlVdeuV6I0oiqogEnTjjhBJtG4+g8bK1bDU6TRIgCGsh3Yjq8TP9gOilct8uXL7d6QlTh6QTali1bhiOPPNLW9WeffVbzxY3C8MMX9ONA586drVGvWxSO9gu+np9//nnblocMGWK3PnCKlmH/0Xi+f1CDXetX7rjjDptu37592GSTTcLmm29u9WiY5HY6efLkmh6nhx56yNb16aefboc+3X777VYvhKiG83U+fPjwsOOOO9p09+7dbXvWaQVa5355CjSOzr/W+uzSpUv42c9+VnMOq6jeh5SvBoQoFIV+edOhOP7PpC9uFRpBheO/yutEWvX86aRZobFZWL4udatfkC+88EIGSSkChShf1zp88tRTT7UTwlE4Wr++L1aDXeFJ9IvyXXfdZQMCqc7rURi6JpTOH3E6jE/nV2o7F2378bkmaDhty4899lh6LlhI1Q8yfk0jfsxtvDvvvNOK1u2NN94YZs2aZfVar9qP6Dpp1bKOCVEouOSvafpyUJ0KO6/CybYudUgUv2YWVrz9Ok3T6Ckcbcu+PXtPiWOfUTi+D4633XjdozjibTrb/lnr3/82aBitv/hw32zrWXX8mFsc8far6Wr5fiREoeB8Z+ZfDCrCsNCFpfXqJ+NrXWudq2g98yVROFqnvo5169s2vVGFpWG2fX+h9avtWHVsy4Xj69K3ZRVf52r0qN7XPwrH17V+off9szcydat1zv6k8bRutR61TrW+/ftR69dvte7ZvhtO69DbGr6/0PrWvO/DtZ1rfVcDQhSKih1W8SXXMeu78Fi/xefrNbl+Wd/FofUar1ufT9ajabDOCydel8ntOTmPhsu2Lqtt3RKiAAAAACAPhCgAAAAAyAMhCgAAAADyQIgCAAAAgDwQogAAAAAgD4QoAAAAAMgDIQoAAAAA8kCIAgAAAIA8EKIAAAAAIA+EKAAAAADIAyEKAKrIcccdFzbYYIOsZcyYMbaMpocPH27ThTRt2rSw5557pueKr2XLlvX6LAsWLLBlAQCoL0IUAFQRhSiFBlHA8FCjAFXMEKUApedtCv7e/TXr81n02QlSAID6IkQBQJWKQ1Sx6bU8pBWTQqKK5BOiROui0OERAFCZCFEAUKWyhSjNe/BQ0bR6aPwwwLjew4r4/dl6cxSedJ/3gMWH2enW7/N6hR/n96uIByMVf01/H/Hz6XP4sr6civPXUvH35Y8HAKAufFsAQJVSYEiGqGTvjYcNBaE4YHkwkTh8aBl/rEuGkzgIKcAkpz0U6bn8/cXT/trJ9+FhzR/vr6PP4NNaRtOqEy3rISoZ9gAAyIUQBQBVSoHBg4nLFqI8cGhZ3SceXhQ4vN5L8jnjoCPxaySDU/z4uD5+jvi14/rkc8WvE4co8XAY8xClZQEAqM363yAAgKqhwFDIEJWLniu+vxghStP1CVH+ucTfl4cmeqIAAPVFiAKAKqXAUIgQ5WHEe3k8xLhkOKlviNJttun4tePp5HPlClGa9mV065/VPwcAAHXh2wIAqoyHDS8ekkRBxeuHDh1aM+0BIzntYUTP4XXZ6P7koXS69RCkEj+vgo74vIp4GFKJH5t8H5qPXyf+XHqOeN6pzgMVAAC1IUQBAIrOw0+pUsBT2AIAoD4IUQCAJuE9QKVGPXMEKABAPghRAAAAAJAHQhQAAAAA5IEQBQAAAAB5IEQBAAAAQB4IUQAAAACQhyYPUT7ErV+fwwt11FFHHXXUUUcdddRRR105KI93CQAAAAAlghAFAAAAAHkgRAEAAABAHghRAAAAAJAHQhQAAAAA5IEQBQAAAAB5IEQBAAAAQB4IUQCQNm3atJprVLRs2TJdG2w6rvdplQULFoThw4fXzPfv379m+rjjjks/w1fi1zj88MNrpuOy55572rJ6fLb7VST5Xrxke12n95tc3o0ZMybjPi+6z+VaLl7G6bMk34/qsj1eJV4/XuL1myz6PPHz+XuI3+PQoUNrppPF/87x6+qxta1D0f3+d3K1vU/dF8u2jIovl3wur/fPqvft216uZePtQ58PAFA4hCgAiMQhI25Ix9PekI2p4e0N1bhBnqTnUb039n3ZZCPZ572BHDeC48Z78r348v78MX+tbJ9Fn1uS70f0XMnnSy7nDfb4fcbrMubv3+/396Pn8sfr+TzgiF5fy8bvQ4/z9+3rVSX+LFpe8/FraBl/HX8vcZ0/V22SryW53r/q4vXpkp/RX9efI/mZ9RzJdefPm2396Hn8uQAAhVX7twQAVBk1Tr1BGjdovREuyeAieowvq1t/fNyoFTWa43pfNtkYztXoT0q+l+Tzxfy1Y94Y98Z5bY+PJZfz9xl/XtX5+8v2/v2143XrkgHD10tyfTq9lr+H+LMkl/dl4vfj7yOu8+fIRs/pnyvX+0m+/2zq+ozJea2n+H3p/erzSHJZX/cAgOIgRAFAxEOUGqhqlKpIviFKy2uZuCGrZbwR741dfx1vDPtz+3PFjX49xh/nku/Fl9fniCXDUkwNeX+ObO8nm+Ry/hzx6+o+vV/VZwtK/p7yDVF6bX9dF79ff1++zmKq1/26L+bvP37NXPy5tXyu9ZN8/9kkl/FtxsWfOZ6P61y8rJ4nuX7Enz+5bQAA8rd+KwAAqpwamN5A9UanGspxQ98b6jE9xhvmulVRAzlutGqZuLEr3hiPiz+PeKPfiz/O+Xvxkq3xLP462Rr98ftMvp9cIaGu961pn/f7kxoSorwkP6fP+3P6Msn15eszfq/OH6eS7T1JvH0k/76x5PvPxh/vJfle/TPH9f7+vfhr+7Jesr1/356zvV8AQH4IUQAQiRvJ4g3duEGcK0R549QDhDd4det1yYax6nwZ8YauN4LjRr8eE7838fei19atTyf5/bWFKEm+n7pClC+X5J8jLsn37u8pW4Nf7yle5/F602snXzee92WzvWa8PrPxz5VrGX98XLKtg+T7z8aXiV8zFn/mJP+7+98nXlbPmetxAIDCIEQBQEQN+7jx6Q39uEHsDdiYGtIeXtQoVokf6w3tuLEr3oD2+5Ov5432ZIPeXyt+L/7cuYKPN65j/nr+mOT7yaWu5eJ16Msm35e/dr4hKubrIfk+PMQll8+2PvUcyfeQ7bES1/n7j9+nS77/bOJl/H3F7yP5mXWff17RY/zx8bL+vlTi5QEAhUOIAoCIGp1xQ1nixqp4gzdeLr5fDXRvpHvI0WMkbuxKMoz4c3vg8Pm40a9pf7w/v/Pw4M8X89eKG+r+eG9sJ99PLrUtp7r4/YrWj5aP672xnwwwouXjdZpcb6LH++tnex/J5UXL5XofvqzPJz+D7k8+n6+/ZH3y/WeTXCb5XLqN57We4uU179tJcln/+8TL+2f3vzUAoOEIUQCQ5g1PlWSjPNnQ17wvq+K8MauiaZ8Xb8R6yXWdKG/4Jl8jLnqvWi6u88axz3sDO+YBIS4ufu8qyc/salsuvs9DiIcDL3oP8bpWid9rXK+SXG9x0evFzx/Ta+h+l1yffp/ej+6L748fJ/H79fuSz+efN65TySbbMtn+Nl60DvR68fvw7SS5fnzZXHW+nQAAGi773h0AAAAAkBUhCgAAAADyQIgCAAAAgDwQogAAAAAgD4QoAAAAAMgDIQoAAAAA8kCIAgAAAIA8EKIAAAAAIA+EKAAAAADIAyEKAAAAAPJAiAIAAACAPBCiAAAAACAPhCgAAAAAyAMhCgAAAADyQIgCAAAAgDyUZYgaPnx42GCDDazsueeeGXUtW7a0OqdljjvuuPTcOpr35ZP3xRYsWGDLTJs2LV2zjl7DH69lRMt43f77718zHRe9lt6Ppv29u/g5K0n8uVTidal1oL8dCi/exn0blfh/JbldI39an8n/ZV+/XuL1j/xkW7++T0nu69E48XfYmDFj0rUopHj/y36haek7sbb2HjL5vpb9QXZl21rXHzT5z6C65JeteGMySTszldr462T7x9NzJhuhWt6fM9vz+/P4l1Wu+yuFPmeyAe/rTH+rbOsAjaftUEW0fr2xqb+F/y/o70AjtHG0brU+4/2Or3en/2kaSw2Tbf3G61P1lbbPbE6+bxBNs90Wltanf9/plm236Whda5tmndef1pV/n6mtwP4gU8WHKNWpsah6b7w77cR8h5aLXkMbTrbGZrbHx/O1Pb/ei+7TP3X8vir9Hzz5+TSfax2hcLxB5P8LLm40oWGy7Xdilf4/XWy1rV9tz/wQUBhal/G2Wtv3FxomboR6GwBNR+ub/XH9xe0D7YfZXjNVfIjyZbItX58vCX9MthCWLVzFr5F8/vg+PZfek0r8HMn3WGmSn0/z/GMWX7yNaceo7Y4v8cLItt9x2kewjhunrvWb6z7kJ7meNV/p30fNiXXb9LQvZr3Xj9oH8f4gOY91yjpEqTGYLMk/ctyA0f0x3VdbA0cbjYrk+kLR6/kyutVyTs8dv7f48fGyeg6/r5L/wfV54/Uj+ry1/Q3QeGpoJre9bP8raBht07nWpbZt3z+gYWpbv9n2KWgY7Se0X9Ct1PX9iIbx9azC+m1aWt+V3MYqJH1vxfvd5DzWqeieKG8sxiVu0NT1JaHnjx+b7bCR+H0knyv5/MmGbPzlr+fP9pkqSbbPprra/gZovOR61/r2/w3WfeMl9zuxSv5/biqs36aj/UH8nRd/X6KwtK45FLVpaZ2zz6gf/e8ToupW0SEq2UBMPkb3J5eJJe/Tc2f7UtGXjSTfT23Pr+fR+3Ga1/NU8j94ts+mutr+BmgcbWPJ7Sz+O2ib81+e0TDJ/U6skv+fm0qu9at1y7ZbHFqvNPCLj3XctNTWYJ9cf962ldras9WsokNUtn+WujYKf3wy5Ei21xTVqSSXz/X8+oLK9vxatlJ3qvq8yXUhWm/Z6tF4ycDk22i8jRGiGk/rNFsjX/XJ/3HkL9v61T7D1222fSkaTvsD9gvFl9w/o/i032Cd15+3GUTtBvYJmcoyROkfQTt5Ff9yjeviEn+5aoPw+lzXcdLzxM8V87pk0NHOUPXxBha/Vlz0fvWefF6vFcvWGKsE+pzJf8B4HSXXAxon3oa9aDsV1nvhxP/Lyf9drWc0Trb1q1uv84LG8+8xekeKJ94vV+p3famK1z375vrzdRa3pfEVvn0AAAAAIA+EKAAAAADIAyEKAAAAAPJAiAIAAACAPBCiAAAAACAPhCgAAAAAyAMhCgAAAADyQIgCAAAAgDwQogAAAAAgD4QoAAAAAMgDIQoAAAAA8kCIAgAAAIA8EKIAAAAAIA+EKAAAAADIQ1mFqDFjxoQNNtggo+y5557pJQrruOOOs+efNm1auiZ/CxYsCC1btkzPVSd9/vjv5evT66t9/RTT8OHDs/5/+N+CdV9YWte+bvW/j8KJ1y2KJ9c+A4Wh/QL7iKbHem8Yb6ep/Y1MZfdtpAZ4vIP3f4xiNQb1vI0JUdVO6y7eYekLWnUKqF6vv6fmUVha1/rfSDaIVI/C03bNvqI4fL8h2lfQyC+OXPsMFI7aFPruU+FHrKbDes+f9rUennz9YX1lH6JEf9hiJWVtODSMCidbWNL6ZadWHPqfSP6/6H9FhR1iYWk9F2s/hK/4/h7FkW2fgcJItl/0fUj7ovhY7w0T72e1X+AH2EwVEaJE/xTeQPdGYnID8DrfELS81/kGommvV50a916v4rzBpOL/jFrW61TiX/X8i1/T8es4f2y2z1ZJ4s/stG4q/XM3l2SDyIOTtlltb3yRFI6vW61X38egOPjRpXiS+wwUjvYL8b4hOY/iYL3nL9nWztX2rnYVFaJUH/9zqE5fCGrc+JeuHq/pZJ0/p27j59cyPq/nU4mX1/N7MPDXje9PLusNrPj1/TlFy2q5SqTPle2z5apH42m9+vaXFG+bKCz9n6M4tN3SACqe2vYZaJy4fSLJeRQH6z1/yfYB7YXsKrInShRQ1JDxBnqufxjVazl/Tt3GDXo9j15T4uAjej09Nn5diRtQ8fuNv5z0XL6cv1cvyeerFLk+V6V+3lJQV4OotvvQcNqm9T+OwmN/UVx17TPQcMnGe3IexcF6zx8hqn4qIkR5INHOX0XTqtOXrddl++LVcvpHip9Tt1reZQtRydeLn9vvd/Fza1mf9ueQ5GMqVba/geqq4bM3l3ibyybb3wSNx3otDt9fo3jq2meg4ZLtF02zPRcf671hvI0qBM/syj5EeRjxOjVe9CUQT8eBRZLBKZ7WrT9e4hCl59Njdb83kuLp+LX1mpqOn1vzPh2/Jz3On0Pi6Uqh9ZD8B/R1Kbrfp1E48TaX5P8HKKxs2zoaT9uyr1ftP1nHxVHbPgON5z+aqmgaTYP1nr+4TevrD+srqxClP6aCR7LEoSNeRn903XqjJrl8crm4+MaiW6/zx8V1/thszzFixIia6SOOOKJmOn4v/mXl8yqVuKHqM8efS587/swqKKz4f8G3s3jboxFaONrHJNc1Ckf7Xl+/XipxP9ncsu0zUFjxvoJtuOmw3hvG15mHKayPlisAAAAA5IEQBQAAAAB5IEQBAAAAQB4IUQAAAACQB0IUAAAAAOSBEAUAAAAAeSBEAQAAAEAeCFEAAAAAkAdCFAAAAADkgRAFAAAAAHkgRAEAAABAHghRAAAAAJAHQhQAAAAA5IEQBQAAAAB5IEQBAAAAQB4IUQAAAACQB0IUAAAAAOSBEAUAAAAAeSBEAQAAAEAeCFEAAAAAkAdCFAAAAADkgRAFAAAAAHkgRAEAAABAHghRAAAAAJAHQhQAAAAA5IEQBQAAAAB5IEQBAAAAQB4IUQAAAACQB0IUAAAAAOSBEAUAAAAAeSBEAQAAAEAeCFEAAAAAkAdCFAAAAADkgRAFAAAAAHkgRAEAAABAHghRAAAAAJAHQhQAAAAA5IEQBQAAAAD1FsL/B65e7EcxzBhsAAAAAElFTkSuQmCC" alt="" width="849" height="481" vspace="0" hspace="0" border="0" style="width:849px;height:481px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with eribulin in all subsets of the paediatric population in the indication of breast cancer (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with HALAVEN in one or more subsets of the paediatric population for the treatment of rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma. See section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Distribution</u></p><p>&nbsp;</p><p>The pharmacokinetics of eribulin are characterized by a rapid distribution phase followed by a prolonged elimination phase, with a mean terminal half-life of approximately 40&nbsp;h. It has a large volume of distribution (range of means&nbsp;43 to 114&nbsp;l/m<sup>2</sup>).</p><p>&nbsp;</p><p>Eribulin is weakly bound to plasma proteins. The plasma protein binding of eribulin (100‑1000&nbsp;ng/ml) ranged from 49% to 65% in human plasma.</p><p><u>&nbsp;</u></p><p><u>Biotransformation </u></p><p>&nbsp;</p><p>Unchanged eribulin was the major circulating species in plasma following administration of <sup>14</sup>C-eribulin to patients. Metabolite concentrations represented &lt;0.6% of parent compound, confirming that there are no major human metabolites of eribulin.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Eribulin has a low clearance (range of means 1.16 to 2.42&nbsp;l/h/m<sup>2</sup>). No significant accumulation of eribulin is observed on weekly administration. The pharmacokinetic properties are not dose or time dependent in the range of eribulin doses of 0.22 to 3.53&nbsp;mg/m<sup>2</sup>.</p><p>&nbsp;</p><p>Eribulin is eliminated primarily by biliary excretion. The transport protein involved in the excretion is presently unknown. Preclinical in vitro studies indicate that eribulin is transported by Pgp. However it has been shown that at clinically relevant concentrations eribulin is not a Pgp inhibitor in vitro. Additionally, in vivo, concomitant administration of ketoconazole, a Pgp inhibitor, has no effect on eribulin exposure (AUC and C<sub>max</sub>). In vitro studies have also indicated that eribulin is not a substrate for OCT1.</p><p>&nbsp;</p><p>After administration of <sup>14</sup>C-eribulin to patients, approximately 82% of the dose was eliminated in faeces and 9% in urine indicating that renal clearance is not a significant route of eribulin elimination.</p><p>&nbsp;</p><p>Unchanged eribulin represented most of the total radioactivity in faeces and urine.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>A study evaluated the pharmacokinetics of eribulin in patients with mild (Child-Pugh A; n=7) and moderate (Child-Pugh B; n=4) hepatic impairment<strong><em> </em></strong>due to liver metastases. Compared to patients with normal hepatic function (n=6), eribulin exposure increased 1.8-fold and 3-fold in patients with mild and moderate hepatic impairment, respectively. Administration of HALAVEN at a dose of 0.97&nbsp;mg/m<sup>2</sup> to patients with mild hepatic impairment and 0.62&nbsp;mg/m<sup>2</sup> to patients with moderate hepatic impairment resulted in a somewhat higher exposure than after a dose of 1.23&nbsp;mg/m<sup>2</sup> to patients with normal hepatic function. HALAVEN was not studied in patients with severe hepatic impairment (Child-Pugh C). There is no study in patients with hepatic impairment due to cirrhosis. See section 4.2 for dosage recommendation.<em> </em></p><p><em>&nbsp;</em></p><p><u>Renal impairment</u></p><p><u>&nbsp;</u></p><p>Increased eribulin exposure was seen in some patients with moderately or severely impaired renal function, with high between-subject variability. The pharmacokinetics of eribulin were evaluated in a Phase 1 study in patients with normal renal function (Creatinine clearance: &ge; 80 ml/min; n=6), moderate (30-50 ml/min; n=7) or severe (15-&lt;30 ml/min; n=6) renal impairment. Creatinine clearance was estimated with the Cockcroft-Gault formula. A 1.5-fold (90% CI: 0.9-2.5) higher dose-normalised AUC<sub>(0-inf)</sub> was observed in patients with moderate and severe renal impairment. See section 4.2 for treatment recommendations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Eribulin was not mutagenic<em> in vitro</em> in the bacterial reverse mutation assay (Ames test). Eribulin was positive in the mouse lymphoma mutagenesis assay and was clastogenic in the <em>in vivo</em> rat micronucleus assay.</p><p>&nbsp;</p><p>No carcinogenicity studies have been conducted with eribulin.</p><p>&nbsp;</p><p>A fertility study was not conducted with eribulin, but based on non-clinical findings in repeated-dose studies where testicular toxicity was observed in both rats (hypocellularity of seminiferous epithelium with hypospermia/aspermia) and dogs, male fertility may be compromised by treatment with eribulin. An embryofoetal development study in rat confirmed the developmental toxicity and teratogenic potential of eribulin. Pregnant rats were treated with eribulin mesilate equivalent to 0.009, 0.027, 0.088 and 0.133&nbsp;mg/kg eribulin at gestation days 8, 10 and 12. Dose related increased number of resorptions and decreased foetal weight were observed at doses &ge;&nbsp;0.088&nbsp;mg/kg and increased incidence of malformations (absence of lower jaw, tongue, stomach and spleen) was recorded at 0.133&nbsp;mg/kg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ethanol anhydrous</p><p>Water for injections</p><p>Hydrochloric acid (for pH-adjustment)</p><p>Sodium hydroxide (for pH-adjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vials
5 years.

In-use shelf life
From a microbiological point of view unless the method of opening precludes the risk of microbial
contamination the product should be used immediately. If not used immediately, in-use storage times
and conditions are the responsibility of the user.
If not used immediately HALAVEN as the undiluted solution in a syringe should not normally be
stored longer than 4 hours at 25°C and ambient lighting, or 24 hours at 2°C - 8°C.
Diluted solutions of HALAVEN (0.018 mg/ml to 0.18 mg/ml eribulin in sodium chloride 9 mg/ml
(0.9%)) solution for injection should not be stored longer than 24 hours at 2°C - 8°C, unless dilution
has taken place in controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25oC, do not freeze.</p><p>For storage conditions after first opening or dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5 ml type I glass vial, with teflon-coated, butyl rubber stopper and flip-off aluminium over seal,<br />containing 2 ml of solution.<br />The pack sizes are cartons of 1 vial.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>should be exercised in its handling. The use of gloves, goggles, and protective clothing is<br />recommended. If the skin comes into contact with the solution it should be washed immediately and<br />thoroughly with soap and water. If it contacts mucous membranes, the membranes should be flushed<br />thoroughly with water. HALAVEN should only be prepared and administered by personnel<br />appropriately trained in handling of cytotoxic agents. Pregnant staff should not handle HALAVEN.<br />Using aseptic technique HALAVEN can be diluted up to 100 ml with sodium chloride 9 mg/ml (0.9%)<br />solution for injection. Following administration, it is recommended that the intravenous line be flushed<br />with sodium chloride 9 mg/ml (0.9%) solution for injection to ensure administration of the complete<br />dose. It must not be mixed with other medicinal products and should not be diluted in glucose 5%<br />infusion solution.<br />Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                European Knowledge Centre
MosquitoWay
Hatfield
Hertfordshire
AL10 9SN
United Kingdom
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/ 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>